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A B S T R A C T
Background
Gastroesophageal reflux disease (GORD) is said to be the causative factor in up to 41% of adults with chronic cough. However cough
and GORD are common ailments and their co-existence by chance is high. Also cough can induce reflux episodes. Treatment for
GORD includes conservative measures (diet manipulation), pharmaceutical therapy (motility or prokinetic agents, H2-antagonist and
proton pump inhibitors (PPI)) and fundoplication.
Objectives
To evaluate the efficacy of GORD treatment on chronic cough in children and adults with GORD and prolonged cough that is not
related to an underlying respiratory disease i.e. non-specific chronic cough.
Search strategy
We searched the Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE
and EMBASE databases, review articles and reference lists of relevant articles. The date of last search was 24th April 2009.
Selection criteria
All randomised controlled trials (RCTs) on GORD treatment for cough in children and adults without primary lung disease.
Data collection and analysis
Two review authors independently assessed trial quality and extracted. Study authors were contacted for further information.
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Main results
Eighteen studies (5 paediatric, 13 adults) were included. None of the paediatric studies could be included in meta-analysis. In adults,
analysis on use of H2 antagonist, motility agents and conservative treatment for GORDwere not possible (from lack of data) and there
were no controlled studies on fundoplication as an intervention. Nine adult studies comparing PPI (two to three months) to placebo
were analysed for various outcomes in themeta-analysis. Enrolment of participants subjects for two studies were primarily frommedical
clinics and another eight studies were otolaryngology clinic patients or patients with laryngeal symptoms. Using “intention to treat”,
pooled data from studies resulted in no significant difference between treatment and placebo in total resolution of cough, Odds Ratio
0.46 (95% confidence interval (CI) 0.19 to 1.15). Pooled data revealed no overall significant improvement in cough outcomes (end of
trial or change in cough scores). Significant differences were only found in sensitivity analyses. A significant improvement in change of
cough scores was found in end of intervention (two to three months) in those receiving PPI with a standardised mean difference of -
0.41 (95% CI -0.75 to -0.07) using generic inverse variance analysis on cross over trials. Two studies reported improvement in cough
after five days to two weeks of treatment.
Authors’ conclusions
There is insufficient evidence to definitely conclude that GORD treatment with PPI is universally beneficial for cough associated with
GORD in adults. The beneficial effect was only seen in sub-analysis. The optimal duration of such a trial of therapy to evaluate response
could not be ascertained although two RCTs reported significant change by 2-weeks of therapy. Clinicians should be cognisant of a
period (natural resolution with time) and placebo effect in studies that utilise cough as an outcome measure. Future paediatric and
adult studies should be double blind, randomised controlled, parallel design, using treatments for at least two months, with validated
subjective and objective cough outcomes and include ascertainment of time to respond as well as assessment of acid and/or non-acid
reflux.
P L A I N L A N G U A G E S U M M A R Y
Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Cough in association with GORD is common in adults with chronic cough. The objective of this review was to evaluate the effectiveness
of GORD treatment in children and adults with GORD and prolonged cough that is not related to an underlying respiratory disease
i.e. non-specific chronic cough. Thirteen studies fulfilled predetermined criteria but only six could be used in various components of
the meta-analysis including data obtained from trialists. Limited data on children prohibited any meta-analysis. In adults with cough
and GORD, no significant difference was found in clinical cure using proton pump inhibitors (PPI) for cough and GORD. Using other
outcomes, there was also no significant differences between PPI and placebo. This review also highlights the large placebo and time
period effect of treatment for chronic cough. In adults GORD treatment with PPI for cough associated with GORD is inconsistent
and its benefit variable. There was insufficient data to draw any conclusion from other therapies for cough associated with GORD.
In children, the data is also inconclusive; thickened feeds had an inconsistent effect and no studies has examined PPI for cough and
GORD.
B A C K G R O U N D
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002). Worldwide, the desire to reduce the impact
of the symptom of cough is reflected in the billions of dollars spent
on over the counter cough and cold medications (Morice 2002).
Non-specific cough has been defined as non-productive cough in
the absence of identifiable respiratory disease or known aetiology
(Chang 2001). Prolonged or chronic cough has been variously de-
fined as a cough which persists greater than three to eight weeks.
Gastroesophageal reflux (GOR) i.e. reflux of gastric contents into
the oesophagus can be acid or non-acid (volume or alkaline reflux)
and these occur physiologically, especially in the post-cibal state
(AMA 1996).When reflux is ’excessive’, GOR disease (GORD) is
present. Symptoms attributed to GORD range from a variety of
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gastrointestinal/ abdominal symptoms (abdominal pain, halitosis,
water brash etc) to extra-oesophageal symptoms (cough, hoarse-
ness, laryngeal problems, ear disease, dental erosion etc) (AMA
1996). Cohort studies in adults suggest that gastroesophageal
reflux disease (GORD) related to acid, causes 21 to 41% of
chronic non-specific cough, including many with no gastrointesti-
nal symptoms of GORD (Irwin 1990).When successfully treated,
GORD associated cough is associated with a decrease in objective
measurements of cough sensitivity (O’Connell 1994). In animals,
potent acid instillation into the oesophagus causes airway neuro-
genic inflammation (Daoui 2002). In adult humans similar experi-
mentation causes cough in a temporalmanner (within 70 seconds)
(Ing 1994). Although a temporal relationship has been shown in
the laboratory, cough is reported in some earlier studies to only
resolve after a mean time of 169 to 179 days following treatment
for acid-GORD related cough (Irwin 2002a). It is thus not sur-
prising that conflicting data have been reported and others have
shown that acid GORD is associated with, but not the causative
factor for, cough. Also, effective treatment of GORD that resolves
gastrointestinal GORD symptoms may have no effect on objec-
tive pulmonary data (Ferrari 1995). Furthermore like asthma and
GORD, both GORD and cough are common diseases, often co-
exist, and their association does not imply cause and effect (AMA
1996; Rudolph 2001; Rudolph 2003, Vakil 2006). Nevertheless,
several reviews/guidelines suggest a therapeutic trial of three to six
months of GORD treatment for non-specific chronic dry cough
in both adults and children (Corrao 1996; Irwin 2002a; Kiljander
2003).
Current treatment for GORD include conservative anti-reflux
measures (diet, positioning etc), pharmacological approaches [acid
suppressing agents: histamine2 (H2) receptor antagonists, proton
pump inhibitors (PPI) and prokinetic agents: domperidone, ery-
thromycin, metoclopramide and previously cisapride] and surgi-
cal approaches (Nissen or Toupet fundoplication by laparoscopic
or open procedures) (Rudolph 2001).
There are several definitions of GORD. Excessive distal oe-
sophageal acidification is the most common clinical scenario of
GORD and can be defined by the histological presence of reflux
oesophagitis (on biopsy) or distal oesophageal pHmetry (24 hour
pH study) (AMA 1996). Distal pH metry is the most sensitive
method for defining acid GORD and is a standard test recom-
mended for evaluating chronic cough (Chung 1996; Irwin 1998).
In children, acid GORD is present if distal pH metry shows a
reflux index (% time pH < 4) of > 10% in infants, and > 4% in
children aged over 12 months as suggested by GORD guidelines
by the European (Vandenplas 1993) and American paediatric gas-
troenterology groups (Rudolph 2001). Dual channel (proximal
and distal) oesophageal pH metry has also been used in assessing
GORD with arguable clinical use even in the assessment of pa-
tients at risk for upper airway complications of GORD (Rudolph
2001). However there is variation in what constitutes an abnor-
mal reflux index; in adults the definition of abnormal pH metry
consistent with GORD varies from a reflux index of greater than
3.9 to 7.2% (AMA 1996).
A systematic review examining the efficacy of the various treatment
modalities for prolonged non-specific cough in adults and children
and GORD would help clarify the link (or otherwise) between
cough and GORD.
O B J E C T I V E S
To evaluate the effectiveness of GORD treatment in adults and
children with GORD and prolonged cough not related to an un-
derlying respiratory disease i.e. non-specific chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials of any GORD treatment with
cough as an outcome, where cough is not primarily related to an
underlying respiratory disorder (such as cystic fibrosis, asthma,
chronic obstructive airway disease, suppurative lung disease etc)
or medication use (ACE inhibitor).
Types of participants
Adults and/or children with chronic (three or more weeks) non-
specific cough (dry and non-productive cough without any other
respiratory symptom, sign or systemic illness).
Exclusion criteria: cough related to mycoplasma, pertussis and
chlamydia, presence of underlying cardio-respiratory condition,
current or recurrent wheeze (greater than two episodes), presence
of other respiratory symptoms (productive cough, haemoptysis,
dyspnoea), presence of other respiratory signs (clubbing, chest
wall deformity, respiratory noises such as wheeze on auscultation
and other adventitious sounds), presence of any sign of systemic
illness (failure to thrive, aspiration, neurological or developmental
abnormality), presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of therapies for GORD.
Trials only comparing two or more medications without a placebo
comparison group were not included. The following treatment
regimes were evaluated:
1. Anti-reflux conservative measures
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2. H2 receptor antagonists
3. Proton pump inhibitors (PPI)
4. Surgical therapy
Trials that included the use of other medications or interventions
was included if all participants had equal access to such medica-
tions or interventions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures.
Primary outcomes
Proportions of participantswhowere not cured or not substantially
improved at follow up (failure to cure).
Secondary outcomes
1. Proportions of participants who were not cured at follow
up.
2. Proportions of participants who not substantially improved
at follow up.
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores).
4. Proportions experiencing adverse effects of the intervention,
(e.g.. rash, surgical morbidity etc).
5. Proportions experiencing complications e.g.. requirement
for medication change, repeat surgery etc.
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures (i.e. where two or
more assessment measures are reported in the same study, the out-
come measure that is listed first in the hierarchy was used).
1. Objective measurements of cough indices (cough
frequency, cough receptor sensitivity).
2. Symptomatic (Quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the patient (adult or child).
3. Symptomatic (Quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the parents/carers.
4. Symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by clinicians.
5. Relevant airway markers consistent with inflammation.
Search methods for identification of studies
The following topic search strategy was used to identify the
relevant randomised controlled trials listed on the electronic
databases:
(“gastro-oesophageal reflux” OR “gastroesophageal reflux” OR
“gastro-esophageal reflux” OR “reflux” OR “ger” OR “gerd” OR
“acid” OR “esophagus” OR “oesophagus”, all as [textword] or
[MeSH]) AND (“cough” as [textword] or [MeSH])
For the full strategies please see Appendix 2; Appendix 3 and
Appendix 4.
We identified trials from the following sources:
1. The Cochrane Controlled Trials Register (CENTRAL) which
includes the Airways Collaborative Review Group Specialised Tri-
als Register.
2.MEDLINE 1966 to 2009. Topic search strategy combined with
the MEDLINE randomised controlled trial search filter as out-
lined in the Airways Group module.
3. OLDMEDLINE 1951 to 1965. Topic search strategy com-
bined with the Medline randomised controlled trial search filter
as outlined in the Airways Group module.
4. EMBASE 1997 to 2009. Topic search strategy combined with
the EMBASE randomised controlled trial search filter as outlined
in the Airways Group module.
5. The list of references in relevant publications.
6. Written communication with the authors of trials included in
the review when necessary.
Searches are current as of April 2009.
Data collection and analysis
Selection of studies
From the title, abstract or descriptions, two review authors (ABC,
LAG) independently reviewed literature searches to identify po-
tentially relevant trials for full review. Searches of bibliographies
and texts were conducted to identify additional studies. From the
full text using specific criteria, the same two review authors inde-
pendently selected trials for inclusion. Agreement was measured
using kappa statistics. Disagreement was resolved by consensus.
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the fol-
lowing information recorded: study setting, year of study, source
of funding, patient recruitment details (including number of el-
igible participants), inclusion and exclusion criteria, criteria used
for GOR diagnosis, GOR symptoms, randomisation and alloca-
tion concealment method, numbers of participants randomised,
blinding (masking) of participants, care providers and outcome
assessors, dose and type of GORD therapy, duration of therapy,
co-interventions, numbers of patients not followed up, reasons for
withdrawals from study protocol (clinical, side-effects, refusal and
other), details on side-effects of therapy, and whether intention-
to-treat analyses were possible. We extracted data on the outcomes
4Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
described previously. Further information was requested from the
authors if required.
Assessment of risk of bias in included studies
Two review authors independently performed quality assessment
on studies included in the review. Four components of quality
were assessed:
1. Allocation concealment. Trials will be scored as; Grade A:
Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality).
2. Blinding. Trials will be scored as: Grade A: Participant and
care provider and outcome assessor blinded, Grade B: Outcome
assessor blinded, Grade C: Unclear, Grade D: No blinding of
outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocated group. Trials will be
scored as: Grade A: The progress of all randomised participants
in each group described, Grade B: Unclear or no mention of
withdrawals or dropouts, Grade C: The progress of all
randomised participants in each group clearly not described.
(Grade A = high quality).
4. Follow up. Trials will be scored as: Grade A: Outcomes
measured in > 90% (where withdrawals due to complications
and side-effects are categorised as treatment failures), Grade B:
Outcomes measured in 80 to 90%, Grade C: Unclear, Grade D:
Outcomes measured in < 80%. (Grade A = high quality)
While only the allocation concealment quality assessment was dis-
played in the meta-analysis figures, all assessments were included
in Characteristics of included studies. We measured Inter-review
author reliability for the identification of high quality studies for
each component using the Kappa statistic.
Each study was also assessed using a 1 to 5 scale described by Jadad
et al (Jadad 1996) and summarised as follows:
1. Was the study described as randomised? (1 = yes; 0 = no)
2. Was the study described as double blind? (1 = yes; 0 = no)
3. Was there a description of withdrawals and dropouts? (1 =
yes; 0 = no)
4. Was the method of randomisation clearly described and
appropriate? (1 = yes; 0 = no)
5. Was the method of double blinding well described and
appropriate? (1 = yes; 0 = no)
When authors of papers gave additional data, quality assessments
and Jadad scores were based on additional data supplied.
Data synthesis
An initial qualitative comparison of all the individually analysed
studies examined whether pooling of results (meta-analysis) was
reasonable. This took into account differences in study popula-
tions, inclusion/exclusion criteria, interventions, outcome assess-
ment, and estimated effect size. The results from studies that met
the inclusion criteria and reported any of the outcomes of interest
were included in the subsequent meta-analyses. In cross-over trials
(Eherer 2003; Kiljander 2000), when datawas combinedwith par-
allel studies only data from the first arm was used as recommended
(Elbourne 2002) There is methodological arguments of handling
cross over data (Clarke 2003; Elbourne 2002) and we considered
it was invalid to use second arm data given the known period effect
of cough (i.e. cough tends to resolve with time (Chang 2001) and
carry-on effect (studies had short wash time of two weeks com-
pared to eight weeks of therapy in each arm).
For the dichotomous outcome variables of each individual study,
relative and absolute risk reductions were calculated using a mod-
ified intention-to-treat analysis. This analysis assumes that partic-
ipants not available for outcome assessment have not improved
(and probably represents a conservative estimate of effect). Num-
bers needed to treat (NNT) was calculated from pooled data with
’intention to treat’ used as the denominator and calculated using
the formula 1/risk difference (Clarke 2003). Event was defined as
successful treatment defined by absence of cough by end of treat-
ment period.
Imputed correlation coefficient for calculation of standard devia-
tion of change frombaseline (Clarke 2003)was derived fromother
studies in the review. The summary weighted risk ratio and 95%
confidence interval (fixed-effect model) was calculated using the
inverse of the variance of each study result for weighting (RevMan
2002). Data were pooled from similar studies, assuming cough
indices were normally distributed continuous variables. For cross-
over studies, mean treatment differences were calculated from raw
data, extracted or imputed and entered as fixed-effect generic in-
verse variance (GIV) outcome was used to give a weighted SD unit
difference and 95% confidence intervals (RevMan 2008) Hetero-
geneity between the study results was tested to see if it reached
statistical significance using a chi-squared test. The 95% confi-
dence interval estimated using a random-effects model was in-
cluded whenever there were concerns about statistical heterogene-
ity.
Gastrointestinal symptoms were not included in the forest plots
as it is not an objective of this review.
Subgroup analysis and investigation of heterogeneity
Sub-group Analysis:
An a priori sub-group analysis was planned
1. Age: adults or children (aged < 18 years and < 12 months)
2.Definition ofGORDused: acidGORDdefined by pHmetry or
oesophageal biopsy or non acid/volume (alkaline) reflux or ’extra-
oesophageal reflux’.
3. Intervention type: medical or surgical intervention
Medical intervention further sub-grouped to:
a) H2 antagonist;
b) proton pump inhibitor (PPI);
c) conservative therapy.
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Sensitivity analysis
We planned sensitivity analyses to assess the impact of the poten-
tially important factors on the overall outcomes:
1. Sudy quality;
2. Study size;
3. Variation in the inclusion criteria;
4. Differences in the medications used in the intervention and
comparison groups;
5. Differences in outcome measures;
6. Analysis using random effects model;
7. Analysis by “treatment received”;
8. Analysis by “intention-to-treat”; and
9. Analysis by study design-parallel and cross over studies
(added after protocol written).
We had planned to tested for publication bias using a funnel plot.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The 2008 search resulted in 432 potential titles. Of these 10 pa-
pers were retrieved, 6 papers were excluded and 4 new studies
included. One of the included studies (Wo 2006) was identified
from an excluded paper (Coron 2007) that was a generic review
of the subject. All the 4 studies (Chao 2007; Moukarzel 2007;
Pawar 2007; Wo 2006) were supported by the pharmaceutical in-
dustry involved in the product trialled in the study. This updated
Cochrane review now has a total of 18 included studies (14 from
previous version and 4 from current update). See Appendix 1 for
details of results of previous searches. The 2009 search identified
457 potential titles; 15 papers were retrieved but none fulfilled
inclusion criteria. Two studies were added to the excluded studies
list.
Included studies
Paediatrics
There were five studies in children; four in infants and one in chil-
dren. Orenstein and colleagues’ study described increased cough
with thickened feeds as an intervention in a diverse group of infants
with cough and GORD (Orenstein 1992). Although most in the
group were otherwise well infants, some had primary respiratory
disease (hence did not have non-specific cough). FourTwo stud-
ies (Orenstein 1992; Vanderhoof 2003; Chao 2007; Moukarzel
2007 ) reported on the use of specific anti-regurgitation formula
milk (as opposed to thickened formula) in infants with GORD
that included cough as an outcome measure. However Moukarzel
2007 did not provide data specific to cough in the publication.
Orenstein and colleagues’ study described increased cough with
thickened feeds as an intervention in a diverse group of infants
with cough and GORD (Orenstein 1992). Although most in the
group were otherwise well infants, some had primary respiratory
disease (hence did not have non-specific cough). Three studies
were supported (one in part) by the manufacturers of the milk
utilised (Vanderhoof 2003; Chao 2007; Moukarzel 2007) and the
other (Xinias 2003) was excluded because it was an open non-ran-
domised (but controlled) trial.Outcomemeasures of the four stud-
ies on infants varied; in two he multi-centre studies (Vanderhoof
2003, Moukarzel 2007) cough was reported as part of a symptom
complex (with gag or choke, etc) and although the authors pro-
vided further information, the data could not be used for analysis
in this review. In one study only a small number of infants had
cough (9 of 81) (Chao 2007) displayed in outcome 1.1 (no sig-
nificant difference between groups).
The single study in children (Dordal 1994) included children with
asthma; its exclusion criteria were insufficiently defined to allow
classification of participants as having non-specific cough and it
is unclear if the study was a randomised study. There were no
controlled trials on the use of PPIs or surgery in infants or children.
Adults
In adults, thirteen studies were included; eleven were published
articles, one in abstract form (Kopec 2001) and one in a confer-
ence report plus abstract (Ing 1997). Additional data were sought
from all but one author(s), six responded but only three (Eherer
2003; Kiljander 2000; Vaezi 2006) were able to provide additional
data that could be used for the meta-analysis. Although all studies
included cough that was presumed associated with GOR, crite-
ria for entry into the studies varied. In six studies, participants
enrolled through the otolaryngology department had “laryngitis”
symptoms (Eherer 2003; Havas 1999; Noordzij 2001; Steward
2004; Wo 2006). One study based in medical clinics also primar-
ily enrolled participants with chronic ’laryngitis’ (Vaezi 2006). In
these studies where subjects were recruited from otolaryngology
clinics, primary lung disease (such as asthma defined by hyper-
responsiveness) as an exclusion criteria were not as stringent as
they were in the studies enrolled through medical outpatients (Ing
1997; Jaspersen 1999; Kiljander 2000; Ours 1999). Mean age of
participants reported in studies was 46 to 58 years (range 18 to 80
years). Some studies had predominantly males (Eherer 2003; Ours
1999) whereas others had predominantly females (Kiljander 2000;
Steward 2004; Wo 2006). TwoOne study had similar proportions
of males to females (Vaezi 2006; Pawar 2007). In all but one study
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(Jaspersen 1999), presence of GOR (or extra-oesophageal reflux)
were confirmedobjectively.However inVaezi and colleagues study,
only 29% of participants had pHmetry characteristics of GORD
(Vaezi 2006). In most the diagnosis of GOR was made with pH-
metry, and some included dual channels. None of the studies used
alkaline or volume reflux as an entry criteria although oesophageal
manometry was also used in two studies.
There were ten parallel studies and three crossover studies, both
with wash out periods of two weeks. Ten studies compared PPI
to placebo but varying doses and frequency were used. Studies in-
volving participants with ’laryngitis’ (Eherer 2003; El Serag 2001;
Havas 1999; Noordzij 2001; Vaezi 2006; Steward 2004; Pawar
2007) generally used higher doses of PPIs (twice daily regime).
Three studies used omeprazole (Kiljander 2000; Noordzij 2001;
Ours 1999), one used esomeprazole (Vaezi 2006) and the other
three studies used a different PPI, pantoprazole (Eherer 2003; Wo
2006), rabeprazole (Steward 2004; Pawar 2007 ) and lansoprazole
(Havas 1999; El Serag 2001). One study compared PPI to ran-
itidine (Jaspersen 1999) and another was a two factorial design
using cisapride and diet intervention (Kopec 2001). In one study
(Steward 2004) all subjects (i.e. both controls and intervention
groups) also received instructions to life style modification. There
was a single study on H2-antagonist versus placebo (Ing 1997),
published only as a report on an oral presentation and abstract
format. Data from this study was presented graphically (provided
by the author) and could not be used as points on the graph were
unclear (number in the study did not equate to the number of
points on the graph). There were no randomised controlled stud-
ies on surgical intervention.
Length of intervention in the study on H2-antagonist versus
placebo was two weeks each (Ing 1997). In the studies using PPI,
length of intervention was two to three months (or 8 to 12 weeks)
and two study had prolonged follow up post trial (Ours 1999).
Outcome measures for all studies were subjective cough scales of
varying types. Two studies had outcome assessments done mid
way through trial (Havas 1999; Noordzij 2001), one had several
evaluations during the trial (Vaezi 2006) but only one of these
studies provided ’during trial’ cough data in the paper (Noordzij
2001). Objective cough monitoring was not used in any study.
In all but one study, gastrointestinal or “extra-oesophageal” symp-
toms of GORDwere also outcome measures. Adverse events were
specifically mentioned in six studies.
Risk of bias in included studies
Jadad score of the studies varied from 1 to 5; six studies had scores
of 5 (Eherer 2003; Ours 1999; Vaezi 2006; Vanderhoof 2003;
Steward 2004; Wo 2006), three studies scored 4 (El Serag 2001;
Kiljander 2000; Noordzij 2001), three studies scored 3 points
(Havas 1999; Ing 1997; Pawar 2007), three study scored 2 points
(Orenstein 1992; Chao 2007; Moukarzel 2007), and three scored
one point (Dordal 1994; Jaspersen 1999; Kopec 2001). The qual-
ity score also varied: One study scored ’high quality’ in all four cat-
egories (Steward 2004). Five studies (Eherer 2003; El Serag 2001;
Ours 1999; Vaezi 2006; Wo 2006) scored ’high quality’ in three
categories and four studies did have any high quality points for all
four categories. Agreement between the two main reviewers (AC
and LG) for quality of studies was excellent; weighted kappa score
was 0.88 for Jadad score and 0.77 for quality assessment.
In the studies in infants, randomisation and blinding were clearly
described in two studies (Orenstein 1992; Vanderhoof 2003).
Randomisation method and blinding were not mentioned in the
other 2 studies in infants (Chao 2007; Moukarzel 2007) or in the
study in children (Dordal 1994). In the adult studies, the randomi-
sation process was clearly described in four but allocation conceal-
ment was unclear in all but one study (Steward 2004, Figure 1).
Method of blinding (i.e. appearance of placebo) was clearly de-
scribed in five studies (Eherer 2003; Noordzij 2001; Ours 1999;
Vaezi 2006;Wo 2006). There were only four studies with data (in-
cluding data that were sought from authors) that could be utilised
as ’intention to treat’ for selected analysis (Eherer 2003; Kiljander
2000; Ours 1999; Vaezi 2006) without making any assumptions.
Figure 1. Methodological quality graph: review authors’ judgments about each methodological quality item
presented as percentages across all included studies.
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Effects of interventions
The 18 studies included 823 randomised participants (372 paedi-
atrics,476 adults) with 506 (317 paediatrics, 412 adults) complet-
ing the trials. Sixteen articles were published in English, one in
German (Jaspersen 1999) and another in French (Dordal 1994).
In the updated searches of 2005, 2006 and 2007 three studies (El
Serag 2001; Vaezi 2006; Steward 2004) were found from recent
review articles and the numbers above include these papers. Some
of the trialists responded to requests for data. Although entry cri-
teria were fulfilled in some participants, data on cough alone in
these participants was not available on one study (El Serag 2001)
but was available in the other two studies (Vaezi 2006; Steward
2004).
Paediatrics
There were insufficient data in infants and children to be dis-
played in the MetaView graphs as trials in infants were too dis-
similar to be included in a meta-analysis. All four studies in in-
fants found improvement in GORD symptoms referring to the GI
system but data for effect on cough was inconsistent; the smaller
study (Orenstein 1992) described significant increase in cough fre-
quency post feeds when thickened feeds were given, Figure 2. The
multicentre study described decrease in percentage of feeds asso-
ciated with cough/gag/choke episodes in infants given pre-thick-
ened milk (Vanderhoof 2003). Cough/gag/choke was grouped as
a secondary outcome and scored in a binary manner in the study
of Vanderhoof and colleagues (Vanderhoof 2003). Additional in-
formation was sought and provided but authors were unable to
provide data on cough alone (cough was included in symptom
complex with choke or gag or cough). In the Chao 2007 study, the
number of children with cough was small (n=9 out of 81 infants
who completed the study) and the difference between groups was
not significant (outcome 1.1). In the Moukarzel 2007 study, al-
though cough was an outcome measure, cough specific data were
not presented in the paper. In the excluded study Xinias and col-
leagues found no effect of the anti-regurgitation formula milk on
cough (Xinias 2003). Dordal and colleagues described no signifi-
cant effect of cisapride or domperidone on cough presumably sec-
ondary toGORD(Dordal 1994).No adverse events were reported
in any study.
Figure 2. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.1 Clinical failures (still
coughing at end of trial or reporting period).
Adults
Cough outcomes
In the single study comparing PPI toH2-antagonist, 70% of those
on PPI improved versus 30% of participants on H2-antagonist
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(Jaspersen 1999). Data from the only study comparing H2-antag-
onist to placebo was presented graphically and showed improve-
ment in cough scores by intervention in all participants and the
effect was significant by two weeks (Ing 1997).
In the ten studies comparing PPI or cisapride to placebo, all but
two studies showed no difference between improvement of cough
scores in the active versus placebo arms (Eherer 2003; Havas
1999; Kopec 2001; Noordzij 2001; Ours 1999; Steward 2004;
Vaezi 2006; Wo 2006). Only two studies described a significant
difference in favour of PPI (Kiljander 2000; Pawar 2007). In the
meta-analysis the outcomes are described below:
Primary outcome: Failure to cure (outcome 02.01)
This was the only outcome where “intention to treat” data could
be utilised in all included studies for this outcome (Eherer 2003;
Kiljander 2000; Ours 1999; Vaezi 2006) displayed in the forest
plot. PooledOR effect estimate was 0.46 and non significant (95%
CI 0.19 to 1.15, Figure 2). In Wo and colleagues study, the “% of
subjects with adequate relief ” was reported to be similar in both
the PPI group and placebo group (40% and 42% respectively, p=
0.89). As data specific for cough could not be obtained, this study
was not included in the meta-analysis.
Mean cough score at end of trial (outcome 02.02)
In pooled analysis of four studies (Eherer 2003; Kiljander 2000;
Noordzij 2001,Pawar 2007), the effect of active drug of borderline
statistical significance (SMD -0.38, 95% CI -0.77, to 0, P = 0.05,
Figure 3). A pooled analysis of data from crossover studies (Eherer
2003; Kiljander 2000) was also not significant (SMD -0.29, 95%
CI -0.62 to 0.04, ).
Figure 3. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.2 Mean cough score at
end of trial (1st arm crossover/parallel group trials).
Change in cough scores at end of intervention (parallel
group/1st arm crossover data) (outcome 02.03 to 02.05)
Pooled analysis for all six studies (Eherer 2003; Havas 1999;
Kiljander 2000; Noordzij 2001;Steward 2004; Pawar 2007) was
statistically significant (SMD-0.39, 95%CI -0.77 to -0.08, Figure
4), and there was a moderate level of heterogeneity (I square 12%).
The two studies (Kiljander 2000; Noordzij 2001) which utilised
omeprazole showed a significant benefit (SMD -0.71, 95% CI -
1.29 to -0.41) and no significant heterogeneity. The studies that
utilised other PPIs (lansoprazole, rabeprazole or pantoprazole)
(Havas 1999; Eherer 2003; Steward 2004;Pawar 2007) showed
no significant benefit of PPI over placebo. Within each subgroup,
there was no significant heterogeneity, between group test for dif-
ference betweenomeprazole and the other PPIswas non significant
(SMD -0.45, 95% CI -1.13 to 0.23). This subgroup analysis was
post hoc. Kiljander 2000 and Noordzij 2001, the two studies that
used omeprazole were also the studies that reported data at week
four and whilst the study drugs may have an effect over a longer
period than one month, the evidence from our analyses should
be cautiously applied for several reasons. Firstly the sample sizes
of the trials were small, and the sensitivity of the symptom scales
is as yet unqualified. However, data from the two crossover trials
(Eherer 2003; Kiljander 2000) assessing mean change in symp-
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toms may confer some validity to the notion that there is an effect
on symptom change. When these data were pooled using change
from baseline scores, there was a significant difference of -0.41
standard deviation units (95% CI -0.75 to -0.07, Figure 5). The
result with absolute scores was not statistically significant (Figure
6).
Figure 4. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.3 Change in cough
scores (end-beginning of intervention - 1st arm crossover/parallel group trials).
Figure 5. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.4 Change in cough
scores (crossover studies; standardised scale).
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Figure 6. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.5 Absolute cough scores
(crossover studies, standardised scale).
Change in cough scores at week four of intervention
(outcome 02.06)
Two studies (Kiljander 2000; Noordzij 2001) could be utilised
for assessment of time effect i.e. after four weeks of intervention.
The change in cough score was in favour of PPI use but was not
significant (P = 0.09) with a standardised mean difference of -0.51
(95% CI -1.08 to 0.06, Figure 7).
Figure 7. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.6 Change in cough score
after 4 weeks treatment (1st arm cross over/parallel group trials).
Change in cough score between week eight (end of
intervention) and week four (mid-intervention) (outcome
02.07)
Two studies (Kiljander 2000; Noordzij 2001) could be utilised
for assessment of time effect from eight weeks (two months) to
four weeks (one month) of intervention. There was no significant
difference between change in cough score between week eight and
week four (SMD of -0.44 (95% CI -1.04 to 0.16), Figure 8.
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Figure 8. Forest plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.7 Difference in cough
scores at week 8 - week 4 (1st arm cross over/parallel group trials).
Determination of time to respond and duration of treatment ef-
fect was limited. The two studies that reported on scores midway
through trial (at one month (Noordzij 2001) and at six weeks
(Havas 1999)) found no difference in scores between midway
scores versus end of trial scores. In the meta-analysis, whereby raw
data was obtained from Kiljander 2000 (data from Havas 1999
could not be included), no significant effect was found between
week eight and week four. In one crossover study, cough resolved
while on omeprazole in two adults but recurred in the washout
phase (Kiljander 2000). One study that reported time to response
(Ours 1999) was also the only paper that had follow-up post trial
(open non-RCT followed the double blind randomised placebo
controlled parallel trial). The authors reported that cough totally
resolved or showed a downward decline in cough scores in 5 to 14
days in coughers who responded to open label PPI (Ours 1999).
None of the studies reported any significant adverse events to in-
terventions and hence ’number needed to harm’ was not relevant
in this review. Heterogeneity between studies included for meta-
analysis was non-significant for all outcomes analysed. Funnel plot
however looked asymmetrical but study numbers were small. As-
sociation between level of risk and benefit was not possible.
Gastrointestinal symptoms of GORD
All studies with sufficient data provided reported significant im-
provement in GI symptoms over time but treatment arm was no
different from placebo arm in five studies (Eherer 2003; Havas
1999; Noordzij 2001; Pawar 2007; Wo 2006 ). In two studies,
improvement in GORD symptoms could not be determined from
lack of data orGORDsymptomswere presumed absent (Ing 1997;
Kopec 2001).
Laryngeal symptoms and scores
All eight studies that included this outcome measure reported
significant improvement in other laryngitis symptoms over time
(Eherer 2003; El Serag 2001;Havas 1999;Noordzij 2001; Steward
2004; Vaezi 2006;Wo 2006 ). In six studies, the difference in to-
tal symptom improvement was similar in both the treatment arm
and placebo arms (Eherer 2003; Havas 1999; Steward 2004; Vaezi
2006; Pawar 2007; Wo 2006). One study found significant differ-
ences between PPI and placebo in hoarseness and throat clearing
but not in throat pain (Noordzij 2001). Another study (El Serag
2001) described that a higher proportion of participants in the
PPI group (86%) had a complete response when compared to the
placebo group (40%) but no significant difference in laryngoscopy
assessment. One study described no difference between PPI and
placebo in total score but an improvement in cough score in favour
of PPI, yet the objective score in reflux (by video laryngoscopy)
significantly favoured the placebo group (Pawar 2007). Wo and
colleagues described that at the 4 week follow up period post ces-
sation of treatment, those on PPI had a significantly higher recur-
rence of laryngeal symptoms then those on placebo (Wo 2006).
When assessed by laryngoscopy, four studies described significant
improvement in laryngoscopy-based scores but again the improve-
ment in those receiving PPIwas similar to those on placebo (Eherer
2003;Havas 1999; Steward 2004;Vaezi 2006).However,Noordzij
2001 found no significant difference in laryngoscopy scores be-
fore and after treatment in both arms. Pawar 2007 and Wo 2006
described a significant difference between groups, both favouring
the placebo group.
Sensitivity analyses
Limiting analysis to studieswith Jadad score of 5did not change the
primary outcome (proportions not cured) with an effect estimate
of 0.52 95% CI 0.20 to 1.35 (all-inclusive effect estimate 0.46,
95% CI 0.19 to 1.15). It was not possible to perform this on
other outcomes. Varying inclusion criteria by removing studies
of participants enrolled from otolaryngology clinics also did not
change the primary outcome (effect estimate 0.17, 95%CI 0.02 to
1.73). Varying inclusion criteria by limiting studies to participants
with ’laryngitis’ also did not change the primary outcome (effect
estimate 0.24, 95% CI 0.21 to 1.49). It was again not possible
to test this effect on other outcomes in the MetaView. Varying
inclusion criteria by removing studies of participants enrolled from
medical clinics did not alter non-significance of results (altered
’change in cough score’ outcome from all-inclusive SMD -0.4,
95% CI -0.86 to 0.06) to SMD -0.18, 95% CI -0.71 to 0.35).
’Mean cough score at endof trial’ did not significantly changewhen
medical clinic studies were omitted; SMD -0.34, 95% CI -0.97
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to 0.28 and analysis was not possible for the primary outcome.
It was not possible to test for analysis for medication class type
or study size because of all studies were small and only studies on
PPI could be used inmeta-analysis. Analysis by treatment received
did not change the primary outcome i.e. proportions not cured;
effect estimate 0.3 (95% CI 0.06 to 1.44). As analysis for other
outcomes were performed on “treatment received” (not possible
on “intention to treat analysis”), this was not repeated for the
other three outcomes. There was no difference in results when
random effects model was used in all outcome measures shown in
the MetaView. If however data from both arms of the cross-over
studies were treated as parallel studies, a significant difference was
found between week eight and week four (SMD -0.76 (95% CI -
1.27 to -0.25) suggesting that the non significant effect is possibly
related to a small sample size.
D I S C U S S I O N
This systematic review of 18 studies (five in infants/children and
thirteen in adults) has shown the lack of high-level evidence that
the treatment for GORD associated cough improves subjective
cough in participants with non-specific cough universally. There
was no effect in pooled analysis and the beneficial effect was seen
only in the subgroup analysis. TheOR for cough resolution pooled
from four studies was insignificant and if calculated, the number
to treat to achieve cough resolution was high at 14.9 and the
95% confidence interval around the NNT ranged from a negative
number to a positive one which hence includes possible harm.
Hence the CI was not given (Altman 1998) and this emphasises
that treatment was not very different to placebo. This review also
highlights the large placebo and time period effect of treatment
for chronic cough.
In contrast to the low effect of GORD treatment on cough found
in RCTs, in non-controlled trials (see ’Characteristics of excluded
studies’ table) the improvement rate of cough by surgical interven-
tion forGORDassociated cough has been reported as high as 92%
(Wright 2003) with cure rates as high as 81% (Brouwer 2003). For
non-surgical intervention e.g. with PPI alone (Habermann 2002)
or PPI with motility agents (Poe 2003), cough improvement rates
of 86 to 100% have been reported (Habermann 2002; Poe 2003).
The large difference between the effect of treatment of GORD
on cough seen in RCT and uncontrolled trails is likely related
to the period effect and/or placebo effect also reported in other
treatments for cough (Chang 1999). The placebo effect of cough
treatments has been reported to be as high as 85% (Eccles 2002).
The high rate of placebo effect was specifically highlighted in two
of the included studies (Eherer 2003; Noordzij 2001).
The beneficial effects of PPI for cough and GORD was inconsis-
tent; significant only when cough outcomes were change in cough
scores at end of trial of studies which used omeprazole (Kiljander
2000; Noordzij 2001) (both these studies also reported four weeks
change) and in the GIV analysis on cross-over studies (Eherer
2003; Kiljander 2000). Non significant changes were found in the
primary outcome measure of failure to cure, as well as in mean
cough score at end of trial (borderline non-significant) and, when
all studies were combined for change in cough score at end of
trial analysis. While a possible contributor to this is the lack of
power, another possible contributor to the inconsistent and small
treatment effect is that, as cough and GORD are both common
symptoms, the presumed GORD related cough was not caused
by GORD. This explanation suggests that in a high proportion
of cases of presumed GORD related cough, there is in fact an al-
ternative cause for the persistent cough. Indeed cough is the most
common symptom presenting to doctors (Britt 2002). Both GOR
and cough are common diseases, often co-exist and its association
does not imply cause and effect (Field 1999). Indeed both symp-
toms co-existing merely by chance is high and cough can induce
reflux episodes as described in asthma and GORD literature (Field
1999; Zerbib 2002). However, our finding of an effect of therapy
with PPI to improve cough does suggest that in a proportion of
cases of chronic cough with associated GORD, GORD is a con-
tributing cause of cough. There is no other biologically plausible
explanation for the improvement in cough with PPI.
Other possible influences of the results of this review include the
degree of acid inhibition achieved, the length of therapy, the out-
comes of cough measured, and the type of GORD (acid versus
non-acid/volume reflux). The degree of acid inhibition achieved
in the treatment is probably a small factor, if any, given that in the
majority of studies resolution of GORD symptoms (of the gas-
trointestinal system) was achieved. However it is also possible that
different degrees of acid suppression are required to control the
different manifestations of GORD. Subjective cough outcomes
were variable between studies and in all studies, the diary systems
used were non validated systems. Subjective cough monitoring is
subjected to various influences (Chang 1998) and less reliable than
objective cough monitoring in both adults (Hsu 1994) and chil-
dren (Chang 2003; Chang 1998). In large RCTs, the influence of
the outcome measures should be equal in both arms, but if one
medication is more likely to improve symptoms other than cough,
cough specific symptom reporting may be unequally influenced.
This is relevant as in the majority of included studies, resolution
of other GORD symptoms was achieved, which may have influ-
enced cough specific reporting.
Some clinical heterogeneity was present in the participants of the
studies included as the majority but not all participants enrolled
from otolaryngology clinics had cough. However using separate
analysis, the direction of change in favour of PPI use was the
same in patients enrolled from medical or from otolaryngology
clinics. Indeed excluding patients from otolaryngology clinics (or
with laryngitis) did not alter the significance of the primary out-
come. There was no significant statistical heterogeneity in studies
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between omeprazole and other PPIs, but this data is limited by
small sample size and different doses used by the different groups
of trialists. The studies using omeprazole used either 40 mg daily
(Kiljander 2000) or bd (Noordzij 2001) while the dosage for lan-
soprazole was 30 mg bd (Havas 1999), rabeprazole was 20 mg bd
(Steward 2004) and pantoprazole was 40 mg bd (Eherer 2003).
Other outcome analysis would not be possible without the studies
based in otolaryngology clinics, which would have resulted in non
significant changes in all the outcomes shown in the MetaView,
with the exception of change in cough scores at the end of interven-
tion which was significant in the single medical clinic study with
data available. Another recent systematic review on laryngo-pha-
ryngeal reflux (LPR) (where cough is often a dominant symptom),
concluded that “high-dose proton pump inhibitor is no more ef-
fective than placebo in producing symptomatic improvement or
resolution of laryngo-pharyngeal symptoms” (Gatta 2007).
Resolution of cough in response to effective treatment is the ideal
outcome in these trials. However a clinically significant improve-
ment, rather than total resolution of cough, may be relevant and
acceptable to patients with poor quality of life. The magnitude
of change in cough score that constitutes a clinically relevant im-
provement is unknown. TheNNT for clinical significant improve-
ment (as opposed to cough resolution) is unknown. TheCochrane
AirwayGroup’s policy is not to report onNNT (although arguably
easily understood by clinicians) when the OR is not significant.
Under these circumstances, (Altman 1998) clearly states that when
CI for NNT should not be presented.
Data on length of therapy required to achieve a change in cough
score are inconsistent. One study reported significant improve-
ment after two weeks of H2-antagonist in all participants (Ing
1997), which is a less potent acid suppressing agent than PPI
(Rudolph 2001). Ours 1999 made specific reference to the re-
sponse time of 5-14 days in those whose cough was relieved by
PPI in the open label phase. However, in themeta-analysis limited
to two studies where week four outcomes were possible (Kiljander
2000; Noordzij 2001), a trend to improvement was seen at week
four and again at eight weeks but this was not significant. If data
from crossover trials were analysed as parallel trials (i.e. as first
arm data), there was a significant difference between week eight
and week four cough scores. While data on length of therapy is
inconclusive, results from this review suggest that a trial of at least
eight to nine weeks would be long enough to expect a significant
improvement. This is also supported by a RCT comparing two
doses of lansoprazole (30 mg bd to 30 mg daily). In participants
whose cough responded to lansoprazole, the response was seen by
four weeks and extended therapy (12 weeks) conferred no signif-
icant additional benefit (Baldi 2006). There is no RCT data to
support recommendations of a six month therapy trial, in contrast
to uncontrolled observations, that GORD associated cough takes
a mean of a five to six months to take effect (Corrao 1996; Irwin
2002a).
PPIs are currently the most potent non surgical intervention for
acid-GORD and no adverse events were reported in these studies.
The use of these medications as a trial of therapy thus probably has
little risk. However an epidemiology study reported that adults on
PPI or H2 antagonist have an increased risk of having community
acquired pneumonia, adjusted relative risk of 1.89 (95%CI1.36 to
2.62) and 1.63 (95% CI 1.07 to 2.48) respectively (Laheij 2004).
This risk translates to “approximately one case of pneumonia for
every 100 years of patient exposure” (Gregor 2004). Another study
described increased risk of hip fractures associated with PPI use;
the adjusted odds ratio for hip fracture associated with more than
1 year of PPI therapy was 1.44 (95%CI 1.30-1.59) (Yang 2006).
Moreover, use of PPI has been reported to cause cough (Howaizi
2003) and the package insert for omeprazole includes cough as an
adverse event in 1.1% of adults. In contrast to pharmaceutical in-
terventions, there were no studies on surgical intervention, which
carries a small but significant rate of serious adverse events.
Some authors suggest that cough in association with GORD re-
lated to acid reflux can occur with normal pH metry and indices
(i.e. require reflux index of 0%), and that cough can take a pro-
longed time (a year) to settle post GORD intervention (Irwin
2002b). Such assertions are difficult to prove or disprove in the
context of the difficulties with using cough as the primary out-
come measure in studies and the feasibility of the required studies.
The difficulties relating GORD to cough as causative (as opposed
to an association) has been recently summarised (Eastburn 2007).
However considerations of non acid reflux require further stud-
ies and perhaps multichannel intraluminal electrical impedance
monitoring, said to be a more sensitive alternative technology for
evaluating all types of GORD (acid and non-acid) (Shay 2004)
may prove useful.
Limitations of review
The validity of this systematic review is hindered by the disparate
nature of the interventions considered and the resulting small
number studies, with only selected availability of unpublished
data. Given the distribution of effects for the primary outcome,
this may be a reason to suspect publication bias (Figure 9). Fur-
thermore although 18 studies were identified, data could only be
used for a subset of them. Our efforts to obtain numerical out-
come data from a number of investigators have only been partially
successful. This review is also limited by a lack of validated scales
and objective data on cough as well as a lack of allocation conceal-
ment data and possibly by clinical heterogeneity of participants
and medications. The review is primarily concerned with people
who do not have primary lung disease but this as an exclusion
factor could not be stringently applied in all studies. In all but four
studies (Steward 2004; Vaezi 2006; Pawar 2007; Wo 2006), par-
ticipants were selected for gastro-intestinal symptoms or objective
evidence of GORD and most but not all participants had cough.
GORD criteria also varied between studies which may influence
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results. Most studies did not utilise GORD criteria specified by
guidelines published by American and European Gastrointesti-
nal Associations (AMA 1996; Rudolph 2001; Vandenplas 1993).
There is also no data on non-acid reflux.
Figure 9. Funnel plot of comparison: 2 PPI versus placebo (> 18 years), outcome: 2.1 Clinical failures (still
coughing at end of trial or reporting period).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Cough and gastrointestinal symptoms of GORD are common ail-
ments and presence of both symptoms by chance is high (in a co-
hort of patients with chronic cough, the chance occurrence maybe
as high as 25%) (Eastburn 2007). There is insufficient evidence
to definitely conclude that adults that GORD treatment with PPI
for cough associated with GORD is beneficial. The beneficial ef-
fect was only seen in sub-analysis and its effect small. Given the
significant morbidity of chronic cough in many patients, a trial of
therapy with PPI in adults with chronic cough and GORDmaybe
considered but has to be balanced with the reported increased (but
small) risk of pneumonia in adults on acid suppressant therapy. If
a therapeutic or empiric trial of PPI is undertaken for treatment
of cough, symptom improvement seems most likely to occur by
two to eight weeks, although the optimal duration is uncertain.
We would thus recommend that empiric trials not be abandoned
before eight weeks until better evidence exist. However the period
effect (natural resolution with time) of cough is significant. Clin-
icians should also be cognisant of the large influence of placebo
intervention seen in studies that utilise cough as an outcome mea-
sure. It is probable that a proportion of adult patients with chronic
cough are subjected to longer term PPI, because of an initial ap-
parent response due to this placebo effect, when their cough is in
fact not caused by their incidental GORD. There is insufficient
data to support (or refute) common recommendations of diet ma-
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nipulation or use of motility agents either as a single agent or in
conjunction with PPIs in the management of GORD and cough.
In children, there is an absence of data on the utility of PPI for
cough associated with GORD. Data on milk modification for in-
fants and cough with GORD is also insufficient to make specific
recommendations. Until more evidence is available in the form of
well designed RCTs, other causes of cough should be considered
in children with cough and GORD, prior to any consideration
of empiric treatment with a prolonged course of GORD medica-
tions/interventions.
Implications for research
Despite the widely advocated proposal that GORD associated
cough is common and that prolonged treatment is required, there
is paucity of RCT data on how effective GORD management
is, in treating cough associated with GORD. Sufficiently pow-
ered RCTs examining time for improvement and resolution of
cough as well as optimal duration of therapy using valid cough
outcomes are required. These cough outcomes should include ob-
jective tools (e.g. ambulatory cough monitors) and validated sub-
jective cough instruments such as cough specific QoL instruments
(Birring 2003; French 2002) and cough diaries (Chang 1998;Hsu
1994). Studies on prediction of response to treatment would also
be useful for clinical practice. The significant time period effect
and placebo influences on cough as a symptom would render non-
controlled studies difficult to interpret. Design of future RCTs
should be parallel and placebo controlled and have sufficient fol-
low-up time post trial to evaluate possible carry-on effect or recur-
rence of cough post cessation of therapy. All three cross-over stud-
ies reported a significant carry-on effect (Eherer 2003; Ing 1997;
Kiljander 2003); cross-over designed studies should therefore not
be repeated. Objective measurement of reflux (acid and non-acid)
whilst on therapy would also be beneficial. Given the possible sig-
nificant harm of surgical intervention and the recommendation of
surgical intervention if cough does not resolve with non-surgical
intervention for cough presumed associated with GORD symp-
toms (Irwin 1998), the need for a randomised controlled study
of surgical intervention is glaring. Respiratory illness and phar-
macokinetics of medications (Sinaiko 2001) in children are suf-
ficiently different to that in adults to warrant separate studies on
children using child appropriate valid outcomes (Chang 2003).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chao 2007
Methods Single centre, double-blinded, randomised placebo-controlled trial that compared a commercial corn-
starched milk anti-reflux (AR) formula to a regular 1.25% strength formula
Infants given regularmilk at baseline and scintigraphy performed.Diaries collected and repeat scintigraphy
performed using the intervention formula
Randomisation method not well described. Allocation by envelope
Jadad score: 2, High quality score: B, C, A, B
Study was financially supported by a pharmaceutical industry
Participants 100 included infants, 81 completed the 2-month clinical follow-up. Intervention group (n=41): mean
age-90.2 (SD 26.8) days, 21 males, 20 females. Placebo group (n=40): mean age-90.5 (SD 27.4) days, 21
males, 19 females. Only total of 9 children had cough as a symptom
Inclusion criteria: Non breast-fed infants (age 2?4 months) presenting with frequent regurgitation/vom-
iting (> 3 times/day)
Exclusion criteria: Infants with atopic symptoms such as eczema, watery rhinorrhoea or diarrhoea suspect-
ing cow’s milk allergy, presence of mechanical obstruction such as infantile hypertrophic pyloric stenosis
and malrotation (excluded with an upper gastrointestinal barium study)
Interventions A cornstarch thickened anti reflux formula compared to 1.25% strength regular formula for 2 months
Outcomes Diary: mean frequency of episodes of regurgitation, and/or vomiting, mean feeding volume tolerated as
well as associated symptoms (irritability, cough, choking, crying) during the 3 days prior to a visit, and
weight gain
90-min milk scintigraphy with 500 µCI technecium to quantify gastric emptying
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Envelope drawing system, no further information
described
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Dordal 1994
Methods Controlled parallel study comparing cisapride with domperidone and no treatment (as control). At base-
line, patients were examined clinically. They underwent skin prick tests, spirometry, chest X-ray and
gastro-oesophageal imaging (bolus liquid was administered and a computer generated image traced the
path of the liquid through the oesophagus). Gastroesophageal imaging graded from 1-4. 1 = normal, 2 =
partial retention of bolus (5 to 10 secs), 3 = retention of bolus (10 to 20 secs), 4 = prolonged retention of
bolus (> 20 seconds). If gastroesophageal imaging of child >= 2, child eligible
Dropouts: n = 10, 15.4% of those recruited. 4 dropouts from cisapride group (2 from adverse events, 2
lost), 2 from domperidone (lost) and 4 from no treatment group (lost)
Randomisation not mentioned, blinding not described and allocation method not described
Participants 65 children (number screened not given) from outpatients with predominant nocturnal cough (with or
without asthma) andGORD symptoms. 15 of the 55 participants who completed trial had cough without
symptoms of asthma
Median age of groups: cisapride- 6.7 years, SD 2.97 (n = 21, 15 males 6 females); domperidone - 7.05
years, SD 3.05 (n = 23, 10 males 13 females); control - 6.4 years, SD 2.62 (n = 11, 5 males 6 females)
Inclusion criteria: Children with cough (with or without co-exiting asthma), predominantly nocturnal
symptoms, reflux symptoms
Exclusion: none described.
Interventions Cisapride (0.2mg/kg 20mins before each meal) with domperidone (0.2mg/kg 15mins before each meal)
and no treatment (as control) for 12 weeks.
All also received the following: Withhold food 2 hours before bedtime, reduce intake of acidic foods,
lower size of meals, but increase frequency, raise height of the head of the bed by 10 cm and, sleeping on
one’s side
Outcomes 1. Symptoms of cough
2. Gastro-imaging
Notes Data on children without asthma were not provided. No significant difference found between the groups
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Eherer 2003
Methods Randomised double blind, crossover study comparing pantoprazole vs placebo in adults with ’laryngitis’
symptoms (includes cough) and GORD (defined on pHmetry). Patients with inclusion criteria enrolled
fromoutpatients clinic, telescopic video laryngo-stroboscopy performed and screened for exclusion criteria.
Dual channel pHmetry performed and those with excessive reflux (> 4.5% time pH < 4) were eligible and
randomised
Randomisation by blocks of 4 performed by pharmaceutical supplier. Allocation method not described.
Compliance monitoring not described
Dropouts (30% of those randomised) were not described and were not included as treatment failures in
paper. But analysis by ’intention to treat’ was possible with additional data provided by authors
Participants 21 adults (mean age 48 years, range 20-70, 16 males, 5 females) randomised from eligible 22 patients; (62
patients screened) with GORD (diagnosed on pHmetry) and symptoms of laryngitis (cough, nocturnal
cough, sore throat, hoarseness, sore dysphonic attacks, globus sensation) attending otolaryngeal clinic in
a tertiary institution (Karl-Franzens University, Austria). 12 of the 21 had chronic cough, 7 were initially
commenced on placebo, and 5 on pantoprazole. 4 of those with cough (25%) did not complete trial; 2
in each arm
Inclusion: hoarseness for > 2 months, laryngitis or other laryngeal symptoms which includes cough
Exclusion: smokers, other causes of laryngitis, prior operations on laryngeal area, laryngeal malignancy,
COPD
Interventions Placebo or pantoprazole 40mg bd for 3 months, 2 weeks wash out followed by pantoprazole or placebo
for 3 months
Outcomes 1. Laryngeal symptoms (0-72) = sum of frequency of each symptom by intensity of symptom.
2. Oesophageal symptoms (0-48) = sum of frequency of each symptom by intensity of symptom.
3. Laryngeal scoring.
All scored at 2 weeks after completion of treatment phase.
Notes Raw cough scores were scores provided by Dr. Eherer.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
El Serag 2001
Methods Randomised double blind , parallel study comparing lansoprazole vs placebo in adults with ’laryngitis’
symptoms (includes cough) with or withoutGORD(defined on pHmetry). Patients with inclusion criteria
enrolled from otolaryngology outpatients clinic. Video laryngoscopy, dual channel pHmetry, gastroscopy
(some also had oesophageal manometry) performed
Allocation method not described. Compliance monitoring by pill counting
Dropouts (n = 2, 9% of those randomised), one from each arm.
Participants 22 adults randomised from 27 patients screened, with laryngitis with or without GORD (diagnosed on
pHmetry) and symptoms of laryngitis attending otolaryngeal clinic in a tertiary institution (Houston,
Michigan). 14 (64%) of participants had chronic cough. Distal reflux defined as DeMeester score > 14.
7. 21 males, 1 female in study, mean age 59 (SD 12) years in lansoprazole group, 65 (SD 12) years in
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El Serag 2001 (Continued)
placebo group
Inclusion: has (a) ’laryngitis’ symptoms as described in outcome measures, (b) posterior laryngitis as
assessed by video laryngoscopy and (c) absence of concurrent infections or allergic causes of laryngitis
Exclusion: aerodigestive malignancies, radiation therapy, or previous GI surgery
Interventions Lansoprazole 30mg bd or placebo bd for 3 months
Outcomes 1. Symptoms of hoarseness, frequent clearing of throat, dry cough, globus or persistent sore throat for >
3 weeks.
2. Laryngoscopy findings. (no scale used for either)
Notes Authors contacted for further information but no data were provided
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Havas 1999
Methods Randomised double blind, parallel study comparing lansoprazole vs placebo in adults with ’posterior
pharyngolaryngitis’ symptoms (includes cough) with or without GORD (defined on pHmetry). Patients
with inclusion criteria enrolled from otolaryngology outpatients clinic. Video laryngoscopy, dual channel
pHmetry, gastroscopy and oesophageal manometry performed
Randomisation and allocation method not described. Compliance monitoring not described
Dropouts (n = 5, 25% of those randomised) data on which group was not given and not included in
paper’s analysis or described as treatment failures
Participants 20 adults randomised from 100 patients screened, with laryngopharyngeal reflux with or without GORD
(diagnosed on pHmetry) and symptoms of laryngitis attending otolaryngeal clinic in a tertiary institution
(Prince of Wales Hospital, Sydney). Distal reflux defined as pH< 4 for > 4% of time, proximal = pH fall
of >= 3 within nadir of =< 5 with oesophageal acidification. Of the 15 (7 males, 8 females, mean age 52.
9 years) who completed the trial, 8 received lansoprazole and 7 placebo
Inclusion: has ’posterior pharyngolaryngitis’ assessed by video laryngoscopy and symptoms (described in
outcome measures)
Exclusion: severe neurological disorders, chronic airflow limitation, pre-existing anti-secretory medica-
tions, severe oesophagitis seen at endoscopy, professional voice users (singers)
Interventions Lansoprazole 30mg bd or placebo bd for 12 weeks
Outcomes 1. Symptom scores (addition of scores for severity [0-3] to scores for frequency [0-4]) for each of 4
symptoms of laryngitis (chronic cough, hoarseness, throat clearing, sore throat pain).
2. Reflux symptoms scored as above for dysphagia, retrosternal burning pain, acid regurgitation and
odynophagia.
3. Laryngoscopy findings (0-4)
4. Adverse events.
Scores obtained at 6 and 12 weeks and data on cough alone was provided in paper
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Havas 1999 (Continued)
Notes Authors contacted for further information but no data were provided
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Ing 1997
Methods Double blind cross over study comparing ranitidine with placebo. Patients with chronic persistent cough (>
2months) with unknown aetiology after a standard diagnostic evaluation were evaluated. They underwent
pHmetry and histamine airway hyper responsiveness. pHmetry was repeated in 7 participants, 4-6 weeks
after the ranitidine treatment period
Dropouts (n = 1, 4% of those recruited).
Participants 25 patients randomised (number screened not given) from medical outpatients of a tertiary hospital. All
patients had PD20 to histamine > 8 umols. 13 participants had placebo medication in the first treatment
period, and the 11 patients who had ranitidine in the first treatment period (1 dropout described)
Mean age was 46.8 (SEM 3.3) yrs, 11 male, 14 female.
Inclusion: chronic cough and significant gastro-oesophageal reflux (presence of > 12 reflux episodes per
24 hours and time pH < 4 was > 0.7%)
Exclusion: patients with bronchial asthma, chronic bronchitis, allergic rhinitis, sinusitis, post nasal drip,
other respiratory and cardiac diseases, acute respiratory infections occurring within 2 months of the study,
smokers, or using theophylline or angiotensin converting enzyme inhibitors
Interventions Placebo or ranitidine 150mg bd for 2 weeks, 2 weeks wash out followed by ranitidine or placebo for 2
weeks
Outcomes 1. Cough scores (1-4) on a twice daily on diary cards recorded basis
2. Presence of symptoms of GORD.
Notes Study not published other than in abstract and conference report
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Jaspersen 1999
Methods Randomised, parallel study comparison of omeprazole versus ranitidine. Method of allocation not de-
scribed. Study was not double blinded
Compliance monitoring not mentioned.
No withdrawals reported.
Participants 20 adults from outpatients department, with chronic cough, with otherwise normal lung function and
negative clinical and radiological findings. 10 participants in omeprazole group (5 males, 5 females, mean
age 49.4 years SD 16.3) and 10 in ranitidine group (6 males, 5 females, mean age 46.5 SD 19.7)
Inclusion: persistent cough for 8 weeks, negative findings from physical examination, negative radiological
findings, with either symptoms of GORD or positive investigation of GORD (diagnosed by gastroscopy)
, and normal lung function
Exclusion: Diagnosis of chronic asthma, COPD, chronic bronchitis, other oesophageal disease, ACE
inhibitor therapy, ENT abnormalities, or smokers
Interventions Omeprazole 10mg/day or ranitidine 300mg/day for 8 weeks.
Outcomes 1. Cough score (range 0-4)
2. Oesophagitis score (range 0-4)
3. Adverse events.
Outcomes recorded for 8 weeks.
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Kiljander 2000
Methods Randomised double-blind, crossover study comparing omeprazole vs placebo in adults with chronic cough
and GORD (defined on pHmetry). Patients with chronic cough enrolled from pulmonary outpatients
clinic were screened for exclusion criteria. Patients completed one-week observation by diary cards, pH-
metry then performed and those with excessive reflux were randomised
Randomisation and allocation method not described.
Compliance monitored by pill counts after treatment period.
8 did not complete trial (27% of those randomised) were not further described and were not included as
treatment failures. Analysis by intention to treat for primary outcome only
Participants 29 adults (median age 49, IQR 20-74, 10 males, 19 females) randomised from 48 patients screened,
with GORD (diagnosed on pHmetry) and chronic (>= 2months) cough attending pulmonary clinic in a
tertiary institution (Turku University, Finland). 12 initially randomised to placebo and 9 to omeprazole
Inclusion: chronic persistent cough (>= 2 months)
Exclusion: Abnormal chest or sinus radiology, positivemethacholine test, rhinitis, nasal mucosa appearance
of cobblestone or muco-purulent secretions, smokers, asthma, chronic bronchitis, use of angiotensin
converting enzyme inhibitor
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Kiljander 2000 (Continued)
Interventions Omeprazole 40mg per day or placebo for 8 weeks, 2 weeks washout followed by omeprazole or placebo
Outcomes 1. Weekly daytime cough and night time cough (cough disturbing sleep) scores = sum of daily 4 point (0
to 3) scale of symptoms (both has range of 0-21)
2. Weekly gastric symptoms (heartburn, regurgitation, chest pain) = sum of daily 4 point (0 to 3) scale of
symptoms (range 0-63). Average of last 3 weeks at end of each treatment period (8 weeks)
Notes Cough scores obtained from primary author.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Kopec 2001
Methods Partial double-blind parallel randomised placebo controlled trial comparing diet and/or cisapride (2
factorial design). Randomisation of the diet was not blinded, randomisation of cisapride was double-
blinded
After standard diagnostic work-up for chronic cough, participants who met criteria (authors assume that
this predicts patients have an approximate 92% chance of having chronic cough due to GERD) were
randomised and pHmetry performed
Randomisation and allocation method not described.
Dropouts (n = 2, 9.5% of those randomised) were not described and were not included as treatment
failures. Analysis by intention to treat not possible
Compliance monitoring not described.
Participants 21 adults (mean age 53.5 years, SD 12.9) with chronic cough and GORD randomised from outpatients
clinic. (number of eligible patients not given). GORD diagnosed on pHmetry or on barium meal
Inclusion: Adults with chronic cough (> 8 weeks) and presumably GORD related cough
Exclusion: age < 18 years, pregnancy, known contraindications to receiving cisapride, such as known allergy
to themedication, or prolongedQT interval on EKG or concurrent use of medications that might interact
with cisapride to place the patients at risk of a potentially life-threatening cardiovascular complication
Interventions 2 factorial design using usual care diet or anti-reflux diet and cisapride 10mg qid or placebo for 4 months
trial ie 4 arm study
Outcomes Cough scores measured by visual analogue score (VAS) from 0 to 100
Notes No difference found in VAS between groups
Further data provided by author was insufficient for inclusion into meta-analysis
Risk of bias
Item Authors’ judgement Description
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Kopec 2001 (Continued)
Allocation concealment? Unclear Information not available
Moukarzel 2007
Methods Single centre, double-blinded, randomised placebo-controlled trial that compared a commercial pre-
thickened anti-reflux (AR) formula to a regular formula
Medical history was obtained and complete physical examination was performed at entry. All infants
underwent a 24-hour oesophageal pHmonitoring while receiving alternating normal and anti-reflux milk.
Weekly monitoring of episodes of regurgitation, vomiting, coughing, crying, and stool frequency and
consistency. The volume of each feeding during a 24 hours period once weekly was also recorded
Randomisation and allocation method not well described. Jadad score: 2, High quality score: B, C, A, B
Study was financially supported by a pharmaceutical industry
Participants 74 included infants, 60 completed the 1-month clinical follow-up. Mean age of group was 3.24 (SD 1.
28) months, 40 males, 34 females. Intervention group n=28, Placebo group n=32. Mean age of infants
within each group was not described
Inclusion criteria: Non breast-fed infants (aged <6 months) with GER (determined using Orenstein
criteria)
Exclusion criteria: Breast-fed and premature infants, infants with history of wheezing, aspiration pneumo-
nia, apnoea, failure to thrive, anaemia, bleeding, laryngitis, and apparent life threatening events. Infants
already receiving AR or medications that could affect the motility of the gastrointestinal tract. Parents
who subjected infants to overfeeding, dilution errors, and inadequate feeding technique
Interventions A pre-thickened anti reflux formula compared to regular formula for 1 month
Outcomes Diary: episodes of regurgitation, vomiting, coughing, crying, and stool frequency and consistency
Data relating to pHmonitoring (reflux index, oesophageal clearance, etc), electrogastrography (a cutaneous
recording of gastric myoelectrical activity
Notes Wrote to authors 31st May 2008
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Noordzij 2001
Methods Randomised double blind, parallel study comparing omeprazole vs placebo in adults with ’laryngitis’
symptoms (includes cough) and GORD (defined on pHmetry)
Patients with inclusion criteria enrolled from outpatients clinic. Video-laryngo-stroboscopy performed
and screened for exclusion criteria. Dual channel pHmetry then performed and those with reflux were
eligible and randomised
Randomisation and allocation method not described.
Compliance monitoring not described.
Dropouts (6.7% of those randomised) were included in analysis but not described as treatment failures.
Analysis by intention to treat not possible
Participants 30 adults randomised from 53 patients screened) with GORD/laryngopharyngeal reflux (diagnosed on
pHmetry) and symptoms of laryngitis attending otolaryngeal clinic in a tertiary institution (University
of Virginia). 15 participants in omeprazole group (8 males, 7 females, mean age 51.7 years) and 15 in
placebo group (8 males, 7 females, mean age 45.3). 2 (6.7 %) did not complete trial, one from placebo
group and the other unknown
Inclusion: one or more symptoms of laryngitis for > 3 months ie symptoms of chronic cough, hoarseness,
excessive phlegm, throat clearing, throat pain, lump in throat and acid reflux (> 4 episodes proximal pH
< 4 or 3 point drop in pH with simultaneous drop in distal pH of < 4)
Exclusion: viral or bacterial laryngitis (undefined), benign vocal fold lesions, occupational exposures
causing laryngitis, history of seasonal allergies or laryngeal malignancy
Interventions Omeprazole 40mg bd or placebo bd for 2 months.
Outcomes 1. Symptom scores (multiplication of severity [0-100] of symptom by frequency [number of days over
last 2 weeks] for each of 6 symptoms of laryngitis (chronic cough, hoarseness, excessive phlegm, throat
clearing, throat pain, lump in throat) and 3 symptoms of GOR (dysphagia, odynophagia and heartburn
2. Adverse events.
Scores obtained at 1 and 2 months and data on cough alone was provided in paper
Notes Authors contacted for further information but no data were provided
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Orenstein 1992
Methods Randomised single blind, cross over study comparing thickened andunthickened feeds on cough associated
with feeds, related to GORD diagnosed by pHmetry, barium swallow or oesophageal biopsy. Assessor was
blinded but not care-giver/nurse who fed infants
Randomisation well described (lottery) but allocation method not described
No dropouts mentioned. Uncertain if analysis was by intention to treat
Participants 25 infants randomised (number screened not given) from outpatients of a tertiary gastroenterology centre
(Children’s Hospital of Pittsburg) referred for GORD
Medianpost natal age 7.5weeks (range 2-26), corrected age 7weeks (-6 to 26), gender not given. Symptoms
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Orenstein 1992 (Continued)
other than cough were irritability in 72%, regurgitation in 60%, apnoea in 28%, history of pneumonia
in 4%
Inclusion criteria: not defined.
Exclusion: concurrent acute infectious respiratory illness, use of prokinetic or acid reducing medications
Interventions Thickened (with rice cereal) and unthickened feeds.
Outcomes Cough frequency during feeds and post prandial per hour.
Notes Results showed that cough frequency when on thickened feeds (3.9) was significantly higher than when
on unthickened feeds (2.2); P = 0.006
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Ours 1999
Methods Randomised double blind, parallel comparison of omeprazole vs placebo in adults with chronic cough and
GORD (defined on pHmetry). Potential participants screened for exclusion criteria. Patients completed
2 weeks observation by diary cards. Those with score of at least 3 were treated with antihistamine and
nasal corticosteroids. If persistent cough remained (score >= 2) oesophageal manometry and pHmetry
were undertaken. Those with GORD were randomised. No withdrawals. After end of trial (12 weeks),
open study performed using omeprazole (one month)
Randomisation by computer but allocation method not described. Compliance monitored by pill counts
after treatment period
All completed trial. Analysis by intention to treat possible
Participants 17 participants randomised from 71 patients screened. Patients with chronic cough enrolled from news-
paper advertisements and outpatients (most were enrolled from community). Mean age and duration of
cough in those randomised were not given. Median age of 36 patients in study prior to results of pHmetry
was 58 years with cough duration of 5 years (interquartile range 2-10)
Inclusion: Aged 18-80 years with chronic cough (>= 6 weeks) with score of >= 2 and with excessive acid
reflux distally or proximal (defined by pHmetry)
Exclusion: Abnormal chest radiology, positive methacholine test, smokers, ex-smokers =< 3 months or
>= 20 pack-yr history of smoking, upper respiratory infection within 8 weeks of entry, use of angiotensin
converting enzyme inhibitor or beta blockers, unable to be weaned off some medications (corticosteroids,
methylxanthines, cough suppressants, beta agonist, anti-cholinergics, or anti- inflammatory agents), his-
tory of pulmonary disease, malignancy, or any co-morbid condition requiring treatment
Interventions Omeprazole 40 mg bd or identical appearing placebo for 12 weeks
Outcomes Cough severity and cough frequency scale (0-8), day and night, measured daily by diary cards for 12 weeks
Response to treatment defined as weekly cough frequency combined with severity score for daytime or
nighttime cough of =< 1 for >= 2weeks consecutively
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Ours 1999 (Continued)
Notes Paper provided failure and success rates but no details on cough scores that can be entered for other meta-
analysis
Open trial results not used for analysis
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
Pawar 2007
Methods Single centre, double-blinded, randomised placebo-controlled trial that compared twice-daily rabeprazole
with placebo for 90 days in adults with “post nasal drip (PND), throat clearing or excessive throat mucus”
Subjects were recruited from otolaryngology clinic atMedical College of Wisconsin or through newspaper
advertisements. Rigid nasal endoscopy, two-site 24-hour pharyngeal pH probe monitoring (pH threshold
=5) and video laryngoscopy performed before Rx. Video laryngoscopy and other 2 outcomes below
repeated on day 90
Non prescription antacids (including H2 antagonists and other PPIs), anti-histamines, decongestants
disallowed to be used concomitantly
Randomisation method and allocation method not described. Jadad score: 3, High quality score B, A, B,
B (no intention to treat analysis)
Study was financially supported in part by a pharmaceutical company
Participants 180 people screened. Of these 53 subjects enrolled, 47 (89%) completed study
Rabeprazol group: n=21 (11 males, 10 female), mean age= 55.6 years (range 40-75). Placebo group: n=
26 (12 males, 14 female), mean age=54.3 years (range 24-76)
Inclusion: Aged 18-80 with main complain of PND, throat clearing or excessive throat mucous
Exclusion: Acute or chronic sinus disease (using nasal endoscopy and/or coronal sinus CT scan), acute
rhino sinusitis, nasal polyps or neoplasms, subjects with vasomotor rhinitis or GER treated in preceding
2 months, smoking, oesophageal or gastric surgery, cardiovascular diease, allergies or pregnancy
Interventions Rabeprazole (20 mg, orally twice daily) or placebo for 90 days
Outcomes Visual analogue scales for PND symptoms, reflux symptom index (higher score = worse), and reflux
finding score (RFS) (higher score = worse)
Notes Symptomatic score significantly improved in intervention arm but the objective score (RFS) was signifi-
cantly worse. Wrote to authors 30th May 2008
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Steward 2004
Methods Single centre randomised double blind, parallel comparison of rabeprazole vs placebo in adults with
chronic cough and GORD (defined on pHmetry). Potential participants screened for exclusion criteria.
Patients completed underwent video strobo-laryngoscopy and undertook questionnaire. 24-hour dual
probe pHmetry was initially part of protocol but was later optional (as patients poorly tolerated it)
Randomisation by computer generated random number table and allocation concealed (using sealed
envelopes). Compliance to PPI/placebo not described
Analysis available for 30 of the 42 (71.4%) subjects randomised. Intention to treat data not available
Participants 194 patients screened, 42 randomised. Patients enrolled from an academic otolaryngology practice at the
University of Cincinnati, USA and from poster and newspaper advertisements. Rabeprazole group (n =
21): mean age (SD) = 52.8 (11.5), 23% males. Placebo group (n = 21): mean age (SD) = 45.8 (11.2), 33.
3% males
Inclusion criteria: 1) age > 18 years; 2) history of hoarseness, throat clearing, non-productive cough, globus
sensation, or sore throat >4 weeks; and 3) physical examination consistent with diagnosis of laryngo-
pharyngeal reflux (ie, edema, erythema, and/or pachydermia)
Exclusion criteria included: 1) previous surgery for gastroesophageal reflux disease, or current gastrostomy
tube; 2) history of hypersecretory disorder (ie, Zollinger Ellison); 3) current tracheotomy tube; 4) current
or recent (within 1 month) use of a proton pump inhibitor; 5) current or recent (within 1 month) use of
a histamine-2 receptor blocker (except over-the-counter use on an as-needed basis <3 times per week); 6)
allergy to proton pump inhibitors; 7) current systemic steroid therapy; 8) previous laryngeal or hypopha-
ryngeal neoplasm; 9) previous radiation therapy to neck; 10) endotracheal tube intubation within past 2
months; 11) diagnosis of vocal cord paralysis; 12) diagnosis of active granulomatous disease (laryngeal or
pulmonary, including sarcoid, Wegener’s, tuberculosis, histoplasmosis, blastomycosis) requiring systemic
therapy; and 13) suspicion for laryngeal neoplasm requiring biopsy for diagnosis
Interventions Rabeprazole 20 mg twice-daily or placebo (identical appearance) for 2 months. All also received lifestyle
modification instructions minimize acid reflux (avoidance of fatty meals, caffeine, alcohol, smoking, and
oral intake within 2 hours of lying down or bedtime, as well as the addition of extra pillows to raise the
head or bedpost blocks to elevate the head of the bed 6 inches)
Outcomes The primary outcome measures: change in total reflux symptom scores and proportion of subjects noting
significant global improvement. The reflux symptom scores were modification of a previously validated
GERD outcome questionnaire that included laryngo-pharyngeal symptoms. The questionnaire included
9 items (heartburn, acid regurgitation, dysphagia, globus, throat clearing, hoarseness, sinus drainage or
phlegm, sore throat, and dry cough). Patients responded to frequency of symptoms (never, monthly,
weekly, several times per week, or daily) and severity of symptoms (none, mild, moderate, severe, very
severe), both scored 0 to 4 on a Likert scale. The total reflux symptom score included sum of frequency
and severity scores for all items
The secondary outcome measures were change in SF36, change in laryngeal grading of videostrobolaryn-
goscopy, and changes in component reflux symptoms scores (frequency, severity, “typical,” “laryngeal,”
“pharyngeal,” and individual symptoms). The component reflux symptom scores were defined as follows:
frequency = sum of all reflux symptom frequency scores; severity = sum of all reflux symptom severity
scores; “typical” = sum of frequency and severity scores for symptoms of heartburn and acid regurgitation;
“laryngeal” = sum of frequency and severity scores for symptoms of hoarseness, dry cough, and throat
clearing; and “pharyngeal” = sum of frequency and severity scores for symptoms of throat clearing, globus
sensation, and phlegm
The tertiary outcome measures were changes in frequency of lifestyle factors related to reflux derived from
the lifestyle questionnaire. The lifestyle questionnaire included 9 items (smoking, alcohol use, caffeine
use, head of bed elevation with blocks, use of 2 pillows to raise head, oral intake within 2 hours of bedtime,
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oral intake within 2 hours of lying down, antacid use, and histamine-2 receptor blocker use). Response
choices included: never, monthly, weekly, several times per week, and daily (0-4 Likert scale)
Notes Cough reported separately in paper. Authors contacted for further data
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes Sealed envelopes concealed randomisation process
from study investigators
Vaezi 2006
Methods Multicenter, randomized, placebo controlled parallel group trial that compared
twice-daily esomeprazole 40 mg with placebo for 16 weeks in adults with suspected chronic laryngeal
symptoms and signs from GOR (but those with significant GI manifestations of GOR were excluded-
see exclusion criteria)
Screening laryngoscopy and screening period were performed. Eligible patients then underwent a 7- to
14-day screening period without treatment, during which they completed a daily diary card on which
they assessed each of 5 symptoms (throat clearing, cough, globus, sore throat, and hoarseness) over the
past 24 hrs on a 7-point Likert scale (0 = none to 6 = very severe). At the end of this period, patients each
identified their single most bothersome symptom as the primary symptom. Patients
eligible for randomization must have completed at least
80% of diary entries, had a cumulative primary symptom score of >= 9, and had >= 3 days withmoderately
severe
symptoms (>= 3 points) over any 7 consecutive days of the 7 to 14 days
Participants randomized in a 2:1 ratio (esomeprazole:placebo) at each center by blocks of six.
After randomization and before receipt of study medication, patients had for ambulatory pharyngoe-
sophageal pH monitoring (APEM). Patients who refused APEM were allowed top articipate. APEM
consisted of two-catheter, three-probe 24-hr study with probe placement in the hypopharynx, proximal
esophagus, and distal esophagus. APEM was assessed by a single, independent investigator at a central
laboratory, blinded to patient-identifying data.
Patients used daily diary card used to assess symptoms each day throughout the 16-week trial. At weeks 0,
4, 8, 12, and 16, the investigator assessed the same symptoms that the patients assessed in their diary cards
using a four-point Likert scale (0 = none to 3 = severe). At the final visit, the investigator also provided an
overall evaluation of improvement
Allocation method not described. Compliance monitored by pill counting. Analysis was by intention to
treat not relevant. Total of 17 (11.7%) withdrawals
Participants 146 participants randomised but one dropped out prior to any Rx (number screened not given). Patients
enrolled from 7 US centres. Esomeprazole group (n = 95): mean age (SD) = 51.5 (15.2), 48 males and
47 females. Placebo group (n = 50): mean age (SD) = 50.5 (14.5), 23 males and 27 females
Inclusion criteria: aged > 18 y and had one or more of the following symptoms for 3 or more consecutive
months before screening: throat clearing, cough, globus, sore throat, or hoarseness; and laryngoscopic
signs consistent with reflux (assessed by a panel via consensus)
Exclusion: clinically significant conditions that might, in the judgment of the investigator, put the patient
at risk, influence the results, affect the patient’s ability to participate in the study, or necessitate surgery
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Vaezi 2006 (Continued)
during the study. Patients who had experienced moderate-to-severe heartburn 3 or more days per week
over a 3-month period before screening; history of respiratory or gastro-intestinal malignancy; radiation
therapy to the head and neck, lung, or gastrointestinal tract; gastroesophageal surgery; chronic sinusitis or
rhinitis in the last year; an allergic cause of laryngitis; an acute traumatic event near the larynx in the last
year; tracheostomy or other significant laryngeal or tracheal surgery; and substance or alcohol abuse in the
past year; other malignancy (except superficial basal cell carcinoma) within the previous 5 years; presence
of an infectious cause of laryngitis in the past 3 months; need for continuous therapy within 1 week
of randomisation with diazepam, phenytoin, mephenytoin, warfarin, anticholinergics, antineoplastics,
prostaglandin analogs, H2-receptor antagonists, steroids (inhaled, oral, or intravenous), promotility drugs,
and sucralfate; use of tobacco products in the past year, any PPI in the last 2 weeks, theophylline, or any
other investigational compound or participation in another investigational drug study in the past 30 days;
and any contraindication to esomeprazole, such as known or suspected allergy or sensitivity to any PPI;
or pregnancy and lactating women
Interventions Esomeprazole 40 mg twice-daily or placebo (identical appearance) for 16 weeks
Outcomes Patients used daily diary card used to assess symptoms each day throughout the 16-week trial. At weeks
0, 4, 8, 12, and 16, the investigator assessed the same symptoms that the patients assessed in their diary
cards using a 4-point Likert scale (0 = none to 3 = severe). At the final visit, the investigator also provided
an overall evaluation of improvement for each symptom as follows: 0 = resolved, 1 = improved, 2 = same,
3 = worse
Laryngoscopic scoring performed at week 8 and 16.
The primary outcome was % patients who had resolution of the primary symptom according to patient
diary card assessment at the final visit. Symptom resolution was defined as a primary symptom severity
score of 0 (none) during the last 7 days of the study, but allowing a score of 1 (minimal severity) for up
to 3 days
Secondary efficacy variables included relief of the primary symptom (by patient ), % symptom-free days,
and% of symptom-free patients, symptom severity change from baseline, and the investigator’s assessment
of symptom-free patients. Relief of the primary symptom was defined as a greater than 50% reduction
from baseline in the primary symptom score during the final week
Notes Authors provided additional cough specific data.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Vanderhoof 2003
Methods Multi-centre randomised double blind, parallel study comparing a pre-thickened formula with placebo
in infants with regurgitant reflux
Parents of infants kept diary cards for 2 days and if eligible randomised. After one week, infants were
reviewed and commenced on pharmacological intervention (ranitidine after day 7/8 and cisapride after
day 14/15). Further follow up till day 35/36
Randomisation well described based on site but allocation method not described
Compliance monitoring done.
Dropouts (n = 12, 10.9% of those randomised. Dropouts included in some analysis but not described as
treatment failures. Analysis by intention to treat not possible
Participants 110 infants randomised (number screened not given) from 6 North American paediatric centres. 7 drop
outs and of remaining 103, mean age of 55 (27males, 28 females) intervention group was 61 days (SD 4)
and that of control group (26males, 23 females) was 58 days (SD 4)
Inclusion: >= 5 regurgitations per day for 2 baseline days, age 14-120 days, gestational age > 37 weeks,
birth weight >= 2.5kg, maternal age >= 18 years
Exclusion: congenital abnormalities interfering with normal feeding or causing repeated regurgitation.
Fever, infectious illness, clinical diagnosis of milk or soy protein allergy, complicated GORD (oesophagi-
tis, haematemesis, recurrent respiratory symptoms, failure to thrive), previous treatment with thickened
formula, or treatment with prokinetic medications 5 days before start of study
Interventions A pre-thickened formula (Enfamil AR) with placebo for 35/36 days, with equal access to additional
pharmacological intervention
Outcomes 1. Regurgitation frequency, regurgitation volume, as documented on daily diary sheets for the first week
and then 2 days/week subsequently.
2. Percentage feeds followed by choke/gag/cough.
3. Trouble sleeping
4. Adverse events
Measures at week 1 and end of participation.
Notes Authors replied but were unable to provide information on cough alone as an outcome measure
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Information not available
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Wo 2006
Methods Single centre, double-blinded, randomised placebo-controlled trial that compared once daily pantoprazole
with placebo for 12 weeks in adults
Protocol was 2-wk run-in, 12-wk randomised treatment, and 4-wk off-treatment follow-up periods.
During the run-in period, subjects filled out weekly diaries. Subjects were seen mid protocol. Naso-
pharyngoscopy, oesophageal manometry and triple sensor pH monitoring performed performed before
Rx. Naso-pharyngoscopy, laryngoscopy and triple sensor pH monitoring performed repeated on end of
week 12. Diaries collected till 4 weeks post Rx
Randomisation method and allocation method clearly described
Jadad score: 5, High quality score: A, A, A, A
Study was financially supported by a pharmaceutical research grant
Participants 42 of 51 who had pH monitoring qualified for study. Of these 42 adults, 39 were randomised and all
completed study
Pantoprazole group: n=20 (7 males, 13 female), mean age= 39 years (range 23-59). Placebo group: n=19
(6 males, 13 female), mean age=37 years (range 23-61)
Subjects were recruited from otolaryngology clinic at University of Louisville or through newspaper
advertisements
Inclusion criteria: Subjects with themain complaint of hoarseness, sore throat, throat burning/pain, throat
clearing, voice loss, cough, excessive throat mucus, globus, or choking for >3 days per wk in the past 2
months. The diagnosis of LPRwas confirmed by laryngeal exam and a positive pH test of the hypopharynx
or distal oesophagus (defined as total number of hypopharyngeal reflux episodes >=3 or distal oesophageal
total time ph< 4 was >=4.2%)
Exclusion criteria: Previous treatment of LPR or GORD, known gastroparesis, connective tissue disorder,
previous endoscopic or surgical antireflux procedure, or gastric surgery. Also those with vocal cord ulcer,
vocal cord granuloma, or laryngeal malignancy seen on naso-pharyngoscopic examination were excluded
Interventions Pantoprazole (40 mg once daily) or placebo for 12 weeks
Outcomes Symptom assessment: weekly diaries of visual analogue scales (0: none to 20: severe) for six laryngeal
symptoms: globus, cough, sore throat, hoarseness, throat clearing, and excessive throat mucus. A total
laryngeal symptom score (0-120) was defined as the sum of the laryngeal symptoms. A similar visual
analogue scale (0-20) was obtained for daytime and nighttime heartburn
Nasopharyngoscopy: Reflux finding score (RFS) (higher=worse)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Randomisation assignment generated by third party
in blocks of 4 with sequential numbering but insuf-
ficient details to be certain if allocation concealment
occurred
APEM: ambulatory pharyngoesophageal pH monitoring; bd: twice daily; GOR: Gastroesophageal reflux; GORD: Gastroesophageal
reflux disease; SD: Standard deviation; vs: versus
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahmad 2004 NonRCT.Prospective followup study of 303 adultswith otolaryngealmanifestations ofGORD. 86%had cough
and choking events presumed secondary to GORD (diagnosed on gastroscopy) were treated with antireflux
therapy (PPI’s in 90%, ranitidine in 3%, Gaviscon in 11%). Complete response to therapy occurred in 25.7%,
no response in 23.1% and the rest had variable response. Adverse events not mentioned
Allen 1998 Non RCT. Prospective follow up study of 195 adults with GORD (diagnosed objectively by combination of
gastroscopy, pHmetry, manometry) treated with Nissen fundoplication. Cough was primary reason for surgery
in 42 (21.5%) patients. Cough scores significant reduced post surgery - 51%were cough free and 31% improved.
Cough scores correlated to dysphagia score (r = 0.233, P = 0.004) but did not relate to scores for heartburn,
pain or regurgitation. Adverse events not mentioned
Allen 2002 Non RCT. Prospective study on predictors for response of cough to laparoscopic fundoplication in 354 adults
(sub group of total 603 fundoplication). Cough was eliminated in 54% of the 81% (287) followed-up and
improved in further 31%. Strongest predictor for response of cough was preoperative cough score (r = 0.62).
Change in cough score on and off PPI ie positive response to PPI (r = 0.296) was a weak predictor. Time scale
of response of PPI was not provided. Those with positive Bernstein test were more likely (P = 0.024) to respond
but predictive value not given. Adverse events not reported
Allen 2004 Non RCT. Follow up of 209 with respiratory symptoms, mainly cough who underwent laparoscopic Nissen
fundoplication. 81% were followed at 6 months, 73% at 2 years, and 60% at 5 years. Cough improved in 83%
at 6 months, 74% at 2 years, and 71% at 5 years
Baldi 2006 Placebo not used. RCT comparing 30 mg bd of lansoprazole to 30 mg daily for 12 weeks. Authors suggest a
positive response at 4 weeks of PPI is an effective criteria for assessing response to PPI treatment
Baldi 2006a Non RCT. Observational prospective study.
Belafsky 2008 Retrospective study on LPR
Brouwer 2003 Non RCT. Prospective study of 29 adults with GORD (diagnosed on gastroscopy) and respiratory symptoms
including cough (n = 19) following laparoscopic Nissen fundoplication. 14 months follow up; 3 required
conversion to open procedure, 4 with major complications. Cough (assessed by subjective score) reported to
resolve completely in 81% and improved in 13%. pHmetry findings in those with respiratory symptoms similar
to those with gastrointestinal symptoms
Chandra 2007 Review paper. No additional references identified.
Chen 2000 Non RCT. Retrospective and prospective study of 90 adults undergoing laparoscopic Nissen fundoplication,
97% with typical GI symptoms, 56% with concurrent non-GI symptoms including cough in 17%. Post surgery
patients with non-GI symptoms improved in 54% but reflux symptoms in 95%. New symptoms of flatulence,
belching, dysphagia, chest and abdominal pain were reported but not measured. Surgical complications not
mentioned
Coron 2007 Review paper. One additional paper identified from references
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Dalby-Payne 2003 Meta-analysis of cisapride for treatment of GORD in children. Cough was not an outcome measure in meta-
analysis
DeMeester 1990 Non RCT. Prospective study evaluating the effect of fundoplication in 17 adults with chronic/persistent res-
piratory symptoms (including cough) and GORD in-patients with or without chest radiograph abnormality.
Surgery was not beneficial only on those whose respiratory symptoms occurred pre reflux event. Those whose
respiratory symptoms occurred during or within 3 mins following or were unrelated to reflux episodes and had
pre surgical normal motility were more likely to benefit
Dore 2007 None placebo controlled RCT. Study used different PPIs (rabeprazole, pantoprazole, esomeprazole and lanso-
prazole) and placebo was not used
Duffy 2003 Non RCT. Prospective study of 148 adults with GORD (diagnosed on gastroscopy, pHmetry or manometry)
undergoing laparoscopic Nissen fundoplication. Of these 31% had cough pre surgery.Modified Gastrointestinal
Quality of Life Index used and no cough specific scores utilised. Improved QOL post surgery reported, surgical
complications not reported
Ekstrom 2000 Non RCT. Prospective study evaluating the effect of fundoplication on 24 patients with severe GORD) and
concomitant asthma (n = 13) or chronic cough (n = 11). In non-asthmatic patients, daytime cough reduced by
47% and night cough by 80% 12 months after surgery
El Hennawi 2004 Non RCT. 64 of 80 adults treated with ’anti-reflux Rx’. Before and after Rx effect described
Eubanks 2001 Non RCT. Before and after PPI study for 3 months relating symptoms of cough, hoarseness and throat clearing
with proximal pHmetry in 14 adults, 7 of whom had cough. 5 of the 7 who improved with PPI had reduction
of > 70% of pharyngeal acid reflux ie 2 of 7 improved without significant reduction. PPI well tolerated, no side
effects reported
Farrell 2001 Prospective non RCT. Symptoms measured pre and post fundoplication (at 6 weeks) in 324 adults of which 67
had cough. Post surgery, cough resolved in 67%, those with atypical symptoms of GORD were more likely to
have had less severe pHmetry indices than those with classical GORD symptoms
Fock 2008 Consensus guidelines. No additional references identified.
Fraser 2000 Prospective non RCT. Symptoms measured pre and post PPI treatment (20 mg daily and if no response by 3
months increased to 40 mg daily) in 87 adults (25 had cough as primary symptom). After 6 weeks, 52% had
good response (undefined)
Gatta 2007 Meta-analysis assessing the effectiveness of medical or surgical therapy for reflux disease in adult patients
with laryngeal or pharyngeal symptoms presumed to be due to gastro-oesophageal reflux disease The authors
concluded that “Therapy with a high-dose proton pump inhibitor is nomore effective than placebo in producing
symptomatic improvement or resolution of laryngo-pharyngeal symptoms”
Greason 2002 Retrospective non RCT in adults with primary respiratory symptoms. Most had abnormal pulmonary function
test
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Grill 1985 Non RCT. Effect of domperidone (0.3-0.6 mg/kg/dose qid) on symptoms and oesophageal and gastric motility
in 15 infants (six boys, mean age 7.9 months), with moderate to severe GORD and upper gastrointestinal
motility disturbances. Vomiting, “spitting,” and coughing improved significantly after 6 weeks therapy
Habermann 1999 Non RCT. 6-week PPI (pantoprozole) used in 29 adults with ’laryngeal’ disorders presumed secondary to
GORD with symptoms including cough. Follow-up at 6 weeks at end of treatment and at 3 months while off
therapy. Significant change in symptoms of heart-burn, hoarseness, sore throat and dyspnoea but no significant
reduction in cough reporting at 6 weeks
Habermann 2002 Non RCT. Prospective study of 14 adults patients with pharyngoesophageal gastric acid reflux (symptoms
include cough) receiving pantoprazole, 40 mg daily for 6 weeks. Significant improvement was observed in all
patients at 6 weeks, in 71% of the patients the 24-hour pH-metry indicated reflux
Hui 2000 Retrospective non RCT- 30 adults with cough and GORD. 60% had symptoms resolve post fundoplication
assessed at 6-36 months. Those without pre-operative nausea were more likely to have resolution of cough
Hunter 1996 Non RCT. Review of 300 adults post laparoscopic fundoplication (252 Nissen and 48 Toupet) for gastroe-
sophageal reflux refractory to medical therapy or requiring daily omeprazole or high-dose H2 antagonists. 64%
had atypical gastroesophageal reflux symptoms (including cough, asthma, hoarseness, chest pain) pre surgery.
Minor complications occurred in 6% and major complications in 2%. Atypical reflux symptoms were elimi-
nated or improved in 87% and no better in 13%
Irwin 1993 Non RCT. Determination of characteristics of 12 adults with cough and GORD (diagnosed on disappearance
or marked improvement or treated with high protein, low fat, anti reflux diet). 75% of cohort had otherwise
silent GORD and pHmetry sensitive in 92% but positive Bernstein and Baker tests unhelpful
Irwin 2002 Non RCT. Report on 8 adults said to have medication resistant GORD (objective diagnosis) and cough, 4 of
whom had previous fundoplication. All had surgery or repeat fundoplication and cough scores reduced post
operative (median of 41 days). One year post fundoplication/repeat fundoplication, although median cough
scores of group were still significantly lower than immediate post surgery, cough scores increased in 5 patients.
Surgical complications not mentioned
Issing 2004 Non RCT. 22 adults with chronic cough, globus pharyngeus, hoarseness or dysphonia (from ENT clinics)
treated with esomeprazole. After 8 weeks, 95% were symptom free
Katzka 1996 Non RCT. Prospective study of 14 adults with persistent symptoms (typical GI and atypical-asthma, cough,
hoarseness, throat burning or undetermined chest pain) despite standard PI therapy (omeprazole 20 mg bd). Of
the 6 with atypical symptoms studied, increased dose of omeprazole (20 mg qid) controlled reflux but did not
control atypical symptoms and pHmetry showed poor correlation between symptoms and acid reflux (defined
as > 50% association of symptoms with pH < 4 within 5 mins)
Leeder 2002 Non RCT. Prospective study on effect of laparoscopic fundoplication in 14 adults objective evidence of GORD
(without oesophagitis on endoscopy or pHmetry). Patients grouped into typical GI (heartburn, volume reflux,
vomiting or regurgitation) or atypical (cough, chest pain, bloating, belching, or choking). 3 of the 7 (43%) in
atypical symptom group had poor outcome post surgery. 2 of these patients had cough but the effect of these 2
patients were not explicitly reported
Monini 2006 Non placebo controlled trial. All with laryngeal symptoms clinically graded as having GORD were given PPI
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Murray 2006 Non RCT. Study described the outcome of patients with cough and paradoxical vocal fold movement disorder
treated with respiratory retraining therapy and management of laryngopharyngeal reflux
Novitsky 2002 Non RCT. Prospective study on effect of fundoplication in 21 adults with chronic cough and GORD and were
unresponsive to PPIs and other medical therapy. Fundoplication was laparoscopic in 18 and open in 3. Cough
improved in 86% of which 62% had complete resolution of cough. No major perioperative complications
occurred
Omari 2006 RCT on effect of baclofen on physiological parameters of GER with no clinical correlates measured as an
outcome, as reported by correspondence to corresponding author
Oridate 2008 Non RCT. Observational study on forty-five patients with laryngopharyngeal and esophageal symptoms receiv-
ing continuous proton-pump inhibitor for up to 6 months
Poe 2003 Non RCT. Prospective study on 56 adults with chronic cough presumed related to GORD (clinical diagnosis)
. Patients treated with PPI and if no response, metoclopromide or cisapride added. In 86%, cough eliminated
or markedly improved after 4 weeks
Songur 2008 Non-RCT examining effect of PPI in adults with symptomatic cough and GERD diagnosed using scintigraphy
Swoger 2006 Prospective controlled non-randomised trial of 25 adults with LPR (of which 30-31% had chronic cough) to
fundoplication vs no fundoplication. No difference found between groups at one year, despite technical success
(increased lower oesophageal sphincter pressure and normalised oesophageal acid) in the fundoplication group
Thoman 2002 Non RCT. Retrospective study on effect of laparoscopic fundoplication 37 adults with cough and GORD.
Complete resolution of cough occurred in 64% with 10% reported improvement. Patients with cough and
GORD were more likely to have dysphagia post surgery
Tibbling 1993 Non RCT. Comparison of adults (mixed respiratory and non-respiratory disease) with GORD treated with
omeprazole (n = 89) and fundoplication (n = 199). Omeprazole (mean 50 days) did not significantly relieved
cough (34% pre and 28% post), but patients who had fundoplication and crural repair showed a highly
significant reduction of cough (34% pre and 7% post)
Tibbling 1995 Similar data set to 1993 paper.
van Zanten 2006 RCT on 224 adults with functional dyspepsia using esomeprazole vs placebo. Cough was not listed amongst
the symptoms examined
Waring 1995 Non RCT. Prospective study evaluating the effect of anti-reflux therapy (omeprazole 20-40 mg/day in 6 and
fundoplication in 21) in 27 adults with GORD and chronic cough or hoarseness. 80% improved including 36%
who became asymptomatic. Improvement of cough was more likely in those whose heartburn was eliminated.
No features of dual pHmetry could predict responders vs non- responders
Wo 1997 Non RCT. Prospective study of 22 adults with posterior laryngitis (4 of whom the major symptom was cough)
treated with 40 mg qid of omeprazole for 8 weeks. Symptom score for cough significantly reduced by 8 weeks
41Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Wright 2003 Non RCT. Prospective study on effect of laparoscopic fundoplication in 145 adults with hiatus hernia and
symptoms suggestive of GORD and laryngopharyngeal reflux. 55% had abnormal pHmetry. 41% of cohort had
cough pre-surgery of which 92% reported improvement. 5 (1.4%) had significant complications (2nd surgery
for bleeding, oesophageal perforation, severe odynophagia required in 3 and pulmonary embolus in 2)
Xinias 2003 Open placebo controlled but non-randomised trial using modified milk for GORD in 56 infants. After 4 weeks
of therapy, there was no change in cough scores although significant reduction in reflux index, vomiting and
regurgitation episodes were found in treatment arm compared to placebo arm
Yang J 2006 Non RCT. Subjects with chronic treated with 8 weeks of PPI.
ENT: Ear nose throat
GI:
GORD: Gastroesophageal reflux disease
PI:
PPI:
qid:
QOL: Quality of life
RCT: Randomised controlled trial
Rx: Treatment
Characteristics of studies awaiting assessment [ordered by study ID]
Morice 2008
Methods RCT on proscriptive or standard anti-reflux advice with brief dietary weight loss intervention
Participants Obese adults with presumed cough associated with reflux
Interventions Dietary
Outcomes Cough QOL
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Thickened versus unthickened feeds (infants)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subjects cured (of cough) at end
of study
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Cough frequency 1 Coughs/hr (Fixed, 95% CI) Totals not selected
Comparison 2. PPI versus placebo (> 18 years)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failures (still coughing at
end of trial or reporting period)
4 191 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.19, 1.15]
1.1 Medical clinics based
enrolment
2 38 Odds Ratio (M-H, Random, 95% CI) 0.17 [0.02, 1.73]
1.2 Otolaryngology based
enrolment
2 153 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.21, 1.49]
2 Mean cough score at end of
trial (1st arm crossover/parallel
group trials)
4 109 Std. Mean Difference (IV, Fixed, 95% CI) -0.38 [-0.77, 0.00]
2.1 Medical clinic based
enrolments
1 21 Std. Mean Difference (IV, Fixed, 95% CI) -0.86 [-1.77, 0.05]
2.2 Otolargyngology based
enrolments
3 88 Std. Mean Difference (IV, Fixed, 95% CI) -0.28 [-0.70, 0.14]
3 Change in cough scores
(end-beginning of intervention
- 1st arm crossover/parallel
group trials)
6 161 Std. Mean Difference (IV, Fixed, 95% CI) -0.39 [-0.71, -0.08]
3.1 studies using omeprazole 2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.29, -0.14]
3.2 studies using other PPI
(lansoprazole, pantoprazole,
rabeprazole)
4 110 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.64, 0.12]
4 Change in cough scores
(crossover studies; standardised
scale)
2 SD units (Fixed, 95% CI) -0.41 [-0.75, -0.07]
4.1 Sub-category 2 SD units (Fixed, 95% CI) -0.41 [-0.75, -0.07]
5 Absolute cough scores (crossover
studies, standardised scale)
2 SD units (Fixed, 95% CI) -0.29 [-0.62, 0.04]
6 Change in cough score after 4
weeks treatment (1st arm cross
over/parallel group trials)
2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-1.08, 0.06]
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7 Difference in cough scores at
week 8 - week 4 (1st arm cross
over/parallel group trials)
2 51 Std. Mean Difference (IV, Fixed, 95% CI) -0.44 [-1.04, 0.16]
Analysis 1.1. Comparison 1 Thickened versus unthickened feeds (infants), Outcome 1 Subjects cured (of
cough) at end of study.
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 1 Thickened versus unthickened feeds (infants)
Outcome: 1 Subjects cured (of cough) at end of study
Study or subgroup Thickened feeds Unthickened feeds Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chao 2007 0/5 2/4 0.09 [ 0.00, 2.68 ]
0.01 0.1 1 10 100
Favours thickened feeds Favours control
Analysis 1.2. Comparison 1 Thickened versus unthickened feeds (infants), Outcome 2 Cough frequency.
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 1 Thickened versus unthickened feeds (infants)
Outcome: 2 Cough frequency
Study or subgroup Coughs/hr (SE) Coughs/hr Coughs/hr
IV,Fixed,95% CI IV,Fixed,95% CI
Orenstein 1992 1.1 (0.89) 1.10 [ -0.64, 2.84 ]
-4 -2 0 2 4
Thickened better Unthickened better
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Analysis 2.1. Comparison 2 PPI versus placebo (> 18 years), Outcome 1 Clinical failures (still coughing at
end of trial or reporting period).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 1 Clinical failures (still coughing at end of trial or reporting period)
Study or subgroup PPI Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medical clinics based enrolment
Kiljander 2000 7/9 12/12 8.2 % 0.12 [ 0.01, 2.85 ]
Ours 1999 7/8 9/9 7.4 % 0.26 [ 0.01, 7.43 ]
Subtotal (95% CI) 17 21 15.6 % 0.17 [ 0.02, 1.73 ]
Total events: 14 (PPI), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Otolaryngology based enrolment
Eherer 2003 2/5 4/6 13.5 % 0.33 [ 0.03, 3.93 ]
Vaezi 2006 79/94 43/48 70.9 % 0.61 [ 0.21, 1.80 ]
Subtotal (95% CI) 99 54 84.4 % 0.56 [ 0.21, 1.49 ]
Total events: 81 (PPI), 47 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 116 75 100.0 % 0.46 [ 0.19, 1.15 ]
Total events: 95 (PPI), 68 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.097)
0.005 0.1 1 10 200
PPI better Placebo better
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Analysis 2.2. Comparison 2 PPI versus placebo (> 18 years), Outcome 2 Mean cough score at end of trial
(1st arm crossover/parallel group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 2 Mean cough score at end of trial (1st arm crossover/parallel group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Medical clinic based enrolments
Kiljander 2000 9 5.89 (5.01) 12 9.91 (4.1) 17.8 % -0.86 [ -1.77, 0.05 ]
Subtotal (95% CI) 9 12 17.8 % -0.86 [ -1.77, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
2 Otolargyngology based enrolments
Eherer 2003 5 0.4 (0.55) 6 1.5 (1.64) 9.3 % -0.79 [ -2.04, 0.47 ]
Noordzij 2001 15 243.3 (346.62) 15 328.2 (473.67) 28.6 % -0.20 [ -0.92, 0.52 ]
Pawar 2007 21 0.29 (0.64) 26 0.5 (1.1) 44.3 % -0.22 [ -0.80, 0.35 ]
Subtotal (95% CI) 41 47 82.2 % -0.28 [ -0.70, 0.14 ]
Heterogeneity: Chi2 = 0.71, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 50 59 100.0 % -0.38 [ -0.77, 0.00 ]
Heterogeneity: Chi2 = 1.98, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 1.27, df = 1 (P = 0.26), I2 =21%
-4 -2 0 2 4
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Analysis 2.3. Comparison 2 PPI versus placebo (> 18 years), Outcome 3 Change in cough scores (end-
beginning of intervention - 1st arm crossover/parallel group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 3 Change in cough scores (end-beginning of intervention - 1st arm crossover/parallel group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 studies using omeprazole
Kiljander 2000 9 -4.55 (5.18) 12 1.33 (5.18) 11.4 % -1.09 [ -2.03, -0.15 ]
Noordzij 2001 15 -112.9 (165.68) 15 -20 (207.16) 19.0 % -0.48 [ -1.21, 0.25 ]
Subtotal (95% CI) 24 27 30.4 % -0.71 [ -1.29, -0.14 ]
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 2.42 (P = 0.015)
2 studies using other PPI (lansoprazole, pantoprazole, rabeprazole)
Eherer 2003 5 -1.4 (2.7) 6 -2.66 (3.14) 6.9 % 0.39 [ -0.81, 1.59 ]
Havas 1999 8 -0.9 (3.37) 7 -0.86 (3.33) 9.8 % -0.01 [ -1.03, 1.00 ]
Pawar 2007 21 -0.52 (1.123) 26 0.08 (0.775) 28.9 % -0.62 [ -1.21, -0.03 ]
Steward 2004 18 -1.2 (2.48) 19 -0.9 (3.02) 24.1 % -0.11 [ -0.75, 0.54 ]
Subtotal (95% CI) 52 58 69.6 % -0.26 [ -0.64, 0.12 ]
Heterogeneity: Chi2 = 3.01, df = 3 (P = 0.39); I2 =0%
Test for overall effect: Z = 1.33 (P = 0.19)
Total (95% CI) 76 85 100.0 % -0.39 [ -0.71, -0.08 ]
Heterogeneity: Chi2 = 5.68, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 1.66, df = 1 (P = 0.20), I2 =40%
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Analysis 2.4. Comparison 2 PPI versus placebo (> 18 years), Outcome 4 Change in cough scores (crossover
studies; standardised scale).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 4 Change in cough scores (crossover studies; standardised scale)
Study or subgroup SD units (SE) SD units Weight SD units
IV,Fixed,95% CI IV,Fixed,95% CI
1 Sub-category
Eherer 2003 -0.34 (0.277) 38.7 % -0.34 [ -0.88, 0.20 ]
Kiljander 2000 -0.45 (0.22) 61.3 % -0.45 [ -0.88, -0.02 ]
Total (95% CI) 100.0 % -0.41 [ -0.75, -0.07 ]
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours PPI Favours placebo
Analysis 2.5. Comparison 2 PPI versus placebo (> 18 years), Outcome 5 Absolute cough scores (crossover
studies, standardised scale).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 5 Absolute cough scores (crossover studies, standardised scale)
Study or subgroup SD units (SE) SD units Weight SD units
IV,Fixed,95% CI IV,Fixed,95% CI
Eherer 2003 -0.161 (0.27) 39.9 % -0.16 [ -0.69, 0.37 ]
Kiljander 2000 -0.375 (0.22) 60.1 % -0.38 [ -0.81, 0.06 ]
Total (95% CI) 100.0 % -0.29 [ -0.62, 0.04 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 2.6. Comparison 2 PPI versus placebo (> 18 years), Outcome 6 Change in cough score after 4
weeks treatment (1st arm cross over/parallel group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 6 Change in cough score after 4 weeks treatment (1st arm cross over/parallel group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kiljander 2000 9 -1.78 (4.47) 12 -1.58 (3.78) 43.1 % -0.05 [ -0.91, 0.82 ]
Noordzij 2001 15 -166.8 (197.17) 15 9.4 (199.98) 56.9 % -0.86 [ -1.62, -0.11 ]
Total (95% CI) 24 27 100.0 % -0.51 [ -1.08, 0.06 ]
Heterogeneity: Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.76 (P = 0.078)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 2.7. Comparison 2 PPI versus placebo (> 18 years), Outcome 7 Difference in cough scores at week
8 - week 4 (1st arm cross over/parallel group trials).
Review: Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults
Comparison: 2 PPI versus placebo (> 18 years)
Outcome: 7 Difference in cough scores at week 8 - week 4 (1st arm cross over/parallel group trials)
Study or subgroup PPI Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kiljander 2000 9 -4.67 (2.17) 12 2.16 (3.9) 30.1 % -2.00 [ -3.09, -0.90 ]
Noordzij 2001 15 53.9 (161.51) 15 10.6 (206.83) 69.9 % 0.23 [ -0.49, 0.95 ]
Total (95% CI) 24 27 100.0 % -0.44 [ -1.04, 0.16 ]
Heterogeneity: Chi2 = 11.09, df = 1 (P = 0.00087); I2 =91%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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A P P E N D I C E S
Appendix 1. Archive of search results (All years to April 2007)
The Airways Group specialised register/search identified 763 potentially relevant titles in the original search in 2004. After assessing
the abstracts, 84 papers were obtained for considered for inclusion into review. The main reason for non-eligibility of studies for review
criteria was the non-controlled non-randomised nature of the respective studies (see table ’Characteristics of excluded studies’). One
controlled but non-randomised study was also excluded (Xinias 2003). Eleven studies were included in the original version of the
review (see ’Characteristics of included studies’), and all but one (Vanderhoof 2003) were single centre studies. The multi-centre study
(Vanderhoof 2003) also the only study supported by commercial interest then. In the 2005 update a further 11 articles were retrieved;
one study was included (El Serag 2001) and the rest were excluded, with two described in the excluded table (El Hennawi 2004; Issing
2004). Following the 2006 search update, eight papers were retrieved. One RCT in adults (Vaezi 2006) was included and another RCT
was excluded (Baldi 2006) as a placebo was not used. The excluded study compared two doses of lansoprazole for adults with chronic
cough (Baldi 2006). Following the 2007 search update, 407 abstracts were reviewed, 12 papers were retrieved; none fulfilled eligibility
criteria. One study that was excluded but should be highlighted was that of a controlled (but non randomised) trial on fundoplication
for laryngopharyngeal reflux (LPR) of which 30-31% of the subjects had chronic cough, the 2nd or 3rd most common symptom
(Swoger 2006). Swoger 2006 described no difference between groups at one year, despite technical success of the fundoplication. A
systematic review on the efficacy of PPIs for LPR was also excluded (Gatta 2007). The paper (Gatta 2007) however revealed a relevant
study that was not found in previous searches; this study (Steward 2004) is now included in this update.
50Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Gastroesophageal Reflux explode all trees in MeSH products
#2 ((gastro-oesophageal next reflux) or (gastroesophageal next reflux) or (gastro-esophageal next reflux) or reflux or ger or gerd or acid
or esophagus or oesophagus)
#3 MeSH descriptor Esophagus explode all trees in MeSH products
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Cough explode all trees in MeSH products
#6 MeSH descriptor Bronchitis explode all trees in MeSH products
#7 cough*
#8 bronchiti*
#9 (#5 OR #6 OR #7 OR #8)
#10 (#4 AND #9)
Appendix 3. MEDLINE search strategy
1. exp COUGH/
2. exp Bronchitis/
3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp GASTROESOPHAGEAL REFLUX/
6. exp Esophagus/
7. (gastro-oesophageal reflux or gastroesophageal reflux or gastro-esophageal reflux or reflux or ger or gerd or acid or esophagus or
oesophagus).mp.
8. 5 or 6 or 7
9. 4 and 8
Appendix 4. EMBASE search strategy
1. exp Coughing/
2. exp Bronchitis/
3. (cough$ or bronchit$).mp.
4. 1 or 2 or 3
5. exp Gastroesophageal Reflux/
6. exp esophagus/
7. (gastro-oesophageal reflux or gastroesophageal reflux or gastro-esophageal reflux or reflux or ger or gerd or acid or esophagus or
oesophagus).mp.
8. 5 or 6 or 7
9. 4 and 8
WH A T ’ S N E W
Last assessed as up-to-date: 9 June 2009.
Date Event Description
24 April 2009 New search has been performed Literature search re-run; no new studies were identified.
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H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 2, 2005
Date Event Description
11 April 2008 New search has been performed Literature search re-run; four new studies were identi-
fied which met the eligibility criteria of the review. The
conclusions were not altered on the basis of the new
trial evidence
5 April 2008 Amended Converted to new review format.
1 August 2007 New citation required but conclusions have not
changed
One new study met the entry criteria of the review
(Steward 2004). This study was identified from a sys-
tematic review on laryngopharyngeal reflux and cough
(Gatta 2007). It contributed data to a secondary out-
come (change in cough scores at end of intervention),
but did not alter the conclusions of the review
6 September 2006 New citation required but conclusions have not
changed
One new study met the entry criteria of the review
(Vaezi 2006). This study contributed data to the pri-
mary outcome (still coughing at end of trial), but did
not alter the conclusions of the review
C O N T R I B U T I O N S O F A U T H O R S
A Chang: initiation, design and direction of review, writing of protocol and review, selection of studies, data extraction, performed
analysis and interpretation of results. LG: selection of studies and data extraction, writing of primary protocol and review. JG: data
extraction; FC: review of manuscript. TJL: data extraction and analysis, interpretation of results and writing of review. The on-line
editor for this review was Dr. M Mckean.
D E C L A R A T I O N S O F I N T E R E S T
Nil.
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